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Abstract 
 
Disease-processes experienced by critically ill patients commonly cause unique 
pharmacokinetic (PK) changes, that may result in drug concentrations that are either sub-
therapeutic or toxic when dosing is based on PK data obtained from non-critically ill patients.  
Ensuring therapeutic dosing of beta-lactam antibiotics in critically ill patient is of increasing 
concern, given the difficult-to-predict PK in this population, frequent use of this antibiotic 
class in treating severe infections and the importance of optimal antibiotic therapy for 
reducing mortality rates.  Therapeutic drug monitoring (TDM), a strategy frequently used in 
dosing drugs with complex PK, has demonstrated potential clinical advantages for improving 
dosing of beta-lactams in the critically ill.  However, the practice of beta-lactam TDM and 
dose optimisation is still limited by a number of factors.  Large-scale data on the adequacy of 
current dosing regimens and optimal PK/pharmacodynamic (PK/PD) targets associated with 
maximal clinical outcome is still limited.  In particular, currently available data on beta-
lactam TDM have not adequately quantified the potentially profound impact of 
hypoalbuminaemia, common among the critically ill, on the PK of the pharmacologically 
active unbound concentration of beta-lactams. 
 
This Thesis aims to describe the application of a beta-lactam TDM-guided dosing program in 
critically ill patients, with the utilization of directly-measured unbound drug concentration 
data.  Specifically, this work will first characterise the impact of altered protein binding in 
critically ill patients on the accuracy of commonly used methods for calculation of unbound 
beta-lactam concentrations (from measured total concentrations).  Secondly, this work will 
describe the achievement of PK/PD targets in relation to directly-measured unbound beta-
lactam concentrations in critically ill patients receiving empiric dosed and TDM-guided beta-
lactam antibiotic treatments.  Finally, the association of beta-lactam concentrations with 
clinical outcome in critically ill patients with blood stream infections will also be 
characterised. 
 
This Thesis comprises of seven chapters. Chapter one introduces relevant PK/PD and beta-
lactam dosing concepts for this Thesis. 
 
Chapter two includes a published review article that systemically analyses the current 
literature at the time on the risk of inadequate drug exposure in critically ill patients and 
  III 
discusses the role of TDM for different class of antibiotics in this setting. This chapter 
specifically addresses available evidence relating to practices of antibiotic TDM, and the 
practical aspects of applying TDM to potentially improve outcomes from severe infections in 
the critically ill.  
 
Chapter three is an original research article that reports findings of a multicentre survey on the 
various approaches used for beta-lactam TDM in intensive care units (ICUs) worldwide.  
 
Chapter four is an original research article that describes findings of a single-centre 
prospective study on unbound beta-lactam concentrations in the critically ill determined by 
two assays.  The aim of this study was to compare the measured unbound concentrations with 
the unbound concentrations conventionally predicted from published protein binding values 
for seven beta-lactam antibiotics commonly used in the critically ill.   
 
Chapter five describes findings of a single-centre prospective study on attainment of 
predefined PK/PD targets in critically ill patients who received empirically dosed and TDM-
guide (using direct-measured unbound drug concentrations) beta-lactam antibiotics. 
Furthermore, the study also aimed to describe patient and treatment factors associated with 
attainment of target concentrations. 
 
Chapter six describes findings of association between beta-lactam exposures, using PK/PD 
indices, and clinical outcomes from a retrospective analysis of prospective studies database.  
Furthermore, the study also aimed to describe patient and treatment factors associated with 
patient outcome. 
 
Chapter seven includes an overall discussion and summary of the findings of this Thesis, and 
explores on potential future research in this area. 
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Chapter 1  Introduction and literature review 
 
Bacterial infections are frequently encountered in intensive care units (ICU) and are 
associated with high healthcare system costs in terms of morbidity, mortality and economic 
burden1.  Antibiotic utilization surveys consistently reveal a bacterial infection prevalence 
>50% amongst critically ill patients.1-3  Beta-lactams, including penicillins, cephalosporins 
and carbapenems, have varied pharmacokinetic (PK) and therapeutic properties and are one of 
the most frequently prescribed groups of antibiotics in ICUs worldwide for management of 
severe infections. 
 
The maintenance of unbound concentrations above the minimum inhibitory concentration 
(MIC) of the targeted pathogen is recognized to be the crucial pharmacodynamic (PD) index 
associated with maximal beta-lactam efficacy.  However, disease processes and treatment 
interventions in critically ill patients can alter antibiotic PK thereby, compromising the ability 
of standard dosing regimens derived from non-critically ill subjects to attain PD targets.  An 
enhanced knowledge of practical methods for ensuring achievement of PD targets is 
necessary for adjusting dosing regimen according to individual patient's needs. 
 
Therapeutic drug monitoring (TDM) is widely used in hospitalised patients for dose 
optimization of aminoglycoside and glycopeptide antibiotics, however it has not been 
adequately evaluated as an intervention for improving beta-lactam dosing.  Clinical PK 
studies have demonstrated that dose adjustment is needed in the majority of patients, although 
a description of the clinical advantages of TDM for beta-lactams is not available.  Previous 
studies on this topic have calculated unbound drug concentrations from total measured 
concentrations and drug protein binding values derived from non-critically ill patients.  
However, changes in the protein binding of beta-lactams in the critically ill may be profound.  
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This research seeks to apply validated beta-lactam assays measuring total and unbound 
plasma drug concentrations for TDM in critically ill patients. We are not aware of any 
previous work examining the utility of beta-lactam TDM based on unbound drug 
concentrations. 
A recent international point prevalence survey of infections in 1265 ICUs from 75 countries 
reported that over 50% critically ill adult patients were considered infected, with 84% of them 
being treated with non-antifungal antibiotics.  Infections of respiratory tract (62%) were the 
commonest, followed by infections of the abdomen, bloodstream, renal and genitourinary 
tract.  For infected patients, the ICU mortality rate doubled (25%) as compared to non-
infected critically ill patients3.   
Beta-lactams are arguably the most important group of antibiotics used in ICU.  In Australia, 
four of the top six antibiotics prescribed in the ICU are beta-lactams, totalling over 60% of 
antibiotics used on a daily basis.2  Similar infection prevalence and antibiotics usage patterns 
have been recorded by European surveillance registry.4   
Appropriate beta-lactam dosing should be considered highly important for the management of 
patients with infections, especially in the ICU.  Early and appropriate antibiotics with 
adequate drug exposure are considered to have favourable impact on outcome.5-9 Garnacho-
Montero et al. evaluated the impact of adequate empirical antibiotic therapy on in-hospital 
mortality in a cohort of ICU patients admitted with sepsis, and demonstrated that adequate 
antibiotic treatment (defined as inclusion of at least one effective drug in the empirical 
antibiotic treatment within the first 24 hours of admission to the ICU) was associated with 
significantly higher in-hospital survival (relative mortality risk reduction of 35%).8  Yost et al. 
extended this data available in this area by showing that not only the choice of antibiotic is 
important, but also the way that drug is administered. In this study, the authors observed that 
in-hospital mortality and survival duration increased significantly when extended-infusion 
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was utilized to increase therapeutic exposure to piperacillin-tazobactam for the treatment of 
Gram-negative infections in a cohort of 359 ICU patients.10  Other data supports the 
importance of appropriate antibiotic therapy in critically ill patients,11-14 however, the changes 
in PK in these patients, can make achievement of therapeutic concentrations of antibiotics 
challenging. 
 
1.1 General pharmacokinetics considerations 
The study of concentration changes of a drug over a given time period, termed PK, can be 
used to determine if the site of infection in a patient is exposed to optimal antibiotic 
concentrations.  The primary PK parameters important in drug dosing include: 
• volume of distribution (Vd): apparent volume of fluid containing the total drug dose  
administered with the same concentration as in plasma; 
• clearance (CL): volume of plasma cleared of drug per unit time; 
• half-life (T1/2): time for plasma concentration to fall by a half; 
• Cmin: the lowest (minimum) concentration during a dosing interval; 
• Cmax: the highest (maximum) concentration during a dosing interval; 
• protein binding: proportion of drug bound to plasma proteins; and 
• AUC: the area under the plasma concentration time curve.  
The PK parameters of selected beta-lactams are shown in Table 1.1.  Beta-lactams are in 
general hydrophilic, with a small Vd corresponding to extracellular volume, 0.1-0.4 L/kg.4, 15  
Protein binding properties vary widely for the beta-lactam family of antibiotics, ranging from 
high binding of over 90% for dicloxacillin, flucloxacillin, ceftriaxone and ertapenem, to 
below 20% for ampicillin, ceftazidime and meropenem.  Half-lives are relatively short 
ranging between 0.5 hour to 2.5 hours, with the exception of 9 hours for ceftriaxone; and 
these drugs are predominantly subjected to renal clearance as unchanged drug, with some 
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modest exceptions.16-18  Disease processes and interventions that critically ill patients undergo 
may alter these PK parameters and make dose optimization challenging.  Most available 
dosing regimens however are derived from PK data obtained from non-critically ill patients, 
jeopardizing their likelihood of achieving PD targets when applied to the critically ill with 
dynamic pathophysiology changes.   
 
Table 1.1  Pharmacokinetic parameters of selected beta-lactam antibiotics commonly used in 
ICUs.   
 
 
Protein binding 
(%) 
t1/2 
(hours) 
% Renal Excretion (as 
unchanged drug) 
Vd 
(L) 
Ampicillin19, 20 15-20 1.0-1.8 90 19.5-27 
Benzylpenicillin21, 22 65 0.5-0.8 58-85 ~24.5* 
Dicloxacillin23, 24 96 0.6-0.8 56-70 ~13.3 
Flucloxacillin25, 26 95 1.0 65.5 9.6-10.0 
Cefalothin27, 28 50-58 0.5-1.0 50-70 12.3* 
Cefazolin27, 29 74-86 1.5-2.5 80-90 ~10 
Ceftazidime27, 30 17 1.5-2.0 80-90 13.6 
Ceftriaxone27 85-95 5.0-9.0 33-67 6-14  
Piperacillin31 30 0.7-1.2 68 10-16  
Meropenem32 2 1.0-1.5 70 15-20 
Ertapenem33 85% at 300 mg/L, 95% at 
<100 mg/L 
4.0 80 8.4* 
 
*Calculated values based on 70kg weight 
 
1.2 General pharmacodynamic considerations 
PK factors are related to the ability of an antibiotic to kill or inhibit the growth of the targeted 
organism by a pharmacokinetic-pharmacodynamic (PD; PK/PD) index.34  In general, PK/PD 
indices that are important in the context of antibiotics include: 
 fT>MIC: the time of a dosing period for which a drug’s unbound (or free) serum 
concentration remains above the minimum inhibitory concentration (MIC)  
 Cmax/MIC: the ratio of the maximum serum antibiotic concentration (Cmax) to MIC 
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 AUC0-24/MIC: the ratio of the area under the concentration time curve during a 24-
hour time period (AUC0-24) to MIC  
The bacterial killing properties of beta-lactams are described as time dependent, with their 
efficacy best related to fT>MIC, although other parameters such as area under the inhibitory 
curve (AUC/MIC or AUIC) have been suggested to be predictive of clinical outcome.5, 35, 36 
The bacterial killing properties of various antibiotic classes are shown in Table 1.2.  
 
Table 1.2. Bacterial killing properties of antibiotic classes with reference to PK/PD indices6, 
17, 37 
Bacterial killing 
property 
PK/PD 
parameter 
Examples 
Time dependent fT>MIC Beta-lactams 
Lincosamides 
Macrolides 
Concentration 
dependent 
Cmax/MIC 
 
Aminoglycosides 
Fluoroquinolones 
Concentration 
dependent with time 
dependence 
 
 
 
AUC0-24/MIC Linezolid 
Vancomycin 
Azithromycin 
Tetracyclines 
Aminoglycosides 
Fluoroquinolones 
 
1.3 Beta-lactams pharmacodynamics 
The PD of beta-lactams have been described in in vitro models, animal in vivo models and in 
retrospective human clinical evaluations. The initial descriptions of time dependent activity 
were described in murine models.  For example, in a granulocytopenic mice model infected 
with Pseudomonas aeruginosa, ticarcillin given every one hour was associated with greater 
bacteriostasis than when the same daily dose was given at a longer intervals, despite only sub-
MIC peak concentrations in both regimens.38  Pharmacodynamically, a fT>MIC of 35–40%, 
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30% and 20% are bacteriostatic for cephalosporins, penicillins and carbapenems, respectively; 
whilst 40% fT>MIC for carbapenems and 50% for penicillins and monobactams and 60-70% 
for cephalosporins are required for maximum bactericidal effect.6, 37-39  However, more 
aggressive PK/PD targets of 70-100% fT>MIC have been suggested for critically ill patients.
40    
 
In a study of seventy-six critically ill patients with bacteraemia and sepsis treated with 
cefepime and ceftazidime, 100% fT>MIC was associated with significantly greater clinical cure 
(82% vs. 33%; P = 0.002) and bacteriological eradication (97% vs. 44%; P < 0.001) than 
patients with fT>MIC lower than 100%.
35 A higher target of maintaining plasma concentrations 
at 4-5 X MIC would theoretically provide maximal antibiotic effect based on in vitro data, 
however the clinical benefits of attaining this target in critically ill patients requires further 
investigation.41-43 
 
A successful antibiotic treatment outcome can be multifactorial and requires consideration of 
the PK of the selected antibiotic, patient physiology and the susceptibility of the targeted 
organism.  Changes in any variables that affect the interrelationship between PK and PD may 
jeopardize treatment outcome. 
 
1.4 Pharmacokinetic considerations in critically ill patients 
Significant variability in the PK of beta-lactam antibiotics among critically ill patients is well 
documented.  A systematic review of the PK of six intravenous beta-lactam antibiotics from 57 
prospective studies in critically ill patients, excluding those undergoing renal replacement 
therapy (RRT), showed significant but variable increases in Vd and Cl amongst critically ill 
patients.44   
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1.4.1 Volume of distribution  
For hydrophilic antibiotics such as beta-lactams, the Vd can increase considerably in patients 
with intra-abdominal diseases,45 multiple organ dysfunction syndrome (MODS),15 trauma, 
burns injury and sepsis.46-48  Capillary leakage and microvascular failure occur as part of the 
disease process lead to fluid shifts,49, 50 necessitating aggressive fluid resuscitation which 
together increases the Vd and therefore decreases the concentrations of beta-lactams.  
However, a prediction of changes in PK between patients has proved challenging, probably 
due to the complex nature of the pathophysiological changes that critically ill patients 
undergo.  Significant variability in ceftazidime pharmacokinetics has been observed between 
acute and hypermetabolic phases of burn injury, where interstitial oedema presents in the later 
phase serves as a reservoir of antibiotic and increases the Vd.51  On the contrary, fluid shifts 
in critically ill patients have no significant effect on the PK of a non-beta-lactam and 
physicochemically different, ciprofloxacin, which intrinsically has larger Vd and better tissue 
penetration properties.52  These examples highlight the need to individualize dosing regimens 
according to antibiotic PK and patient’s physiological status, which at times could be difficult 
due to high inter- and intra-individual variations in PK in critically ill patients.  
 
1.4.2 Clearance  
Beta-lactams are mainly excreted renally in their active forms with their clearances generally 
correlating with creatinine clearance (CLCR). Other physiologically-mediated factors that can 
affect beta-lactam clearance include hepatic function as well as protein binding.  In a study by 
Joynt et al., the clearance of ceftriaxone increased by 100% in critically ill patients with 
severe sepsis or septic shock as compared to normal subjects, resulting in inadequate plasma 
drug concentrations following bolus dosing.  In this study, none of the studied patients had 
renal insufficiency and four had an elevated CLCR >140 ml/min.
53  On the other hand, renal 
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impairment can result in accumulation of beta-lactams to potentially toxic concentrations.  
Nevertheless, since renal clearance is only one of multiple variables that determines the final 
unbound concentration, a patient’s exposure to antibiotics remains difficult to predict.  As an 
example, plasma concentrations of amoxicillin and cloxacillin were found to be unpredictable 
despite doses being adjusted according to renal function, and were only partially correlated 
with plasma creatinine concentration or CLCR.
54  Similarly, imipenem exposure was found not 
to be correlated with renal function parameters or the illness severity of surgical critically ill 
patients.48   
 
1.4.2.1 Augmented renal clearance 
Augmented renal clearance (ARC) is defined as the enhanced elimination of solutes, 
including circulating creatinine and drugs, and has been observed in sub-populations of 
critically ill patients.  Although the underlying mechanisms of augmented renal clearance are 
yet to be fully described, it has been suggested that renal blood flow increases in the presence 
of a systemic inflammatory response syndrome (SIRS), where vasodilation and increased 
cardiac output are manifested.18  In addition, vasoactive agents used for resuscitation in the 
ICU setting could contribute to this phenomenon by further increasing cardiac output and thus 
renal perfusion and CLCR, resulting in low concentrations of renally cleared beta-lactams.
16, 55-
57   
There is limited documented information on the impact of augmented renal clearance on the 
outcome of beta-lactam therapy; however there is emerging mechanistic data highlighting its 
potential importance.  In one study of 54 critically ill patients, antibiotic clearance was found 
to be increased compared to healthy individuals; dose adjustment for ceftriaxone was 
suggested to be unnecessary in majority of patients.56  A CLCR up to 214 mL/min was 
observed in this study and were correlated with ceftriaxone clearance. The PK data from this 
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study were subject to PK model-based simulation and demonstrated the risk of under dosing 
for patients with high glomerular filtration rates (CLCR >120 ml/min and especially >180 
ml/min) or when the MIC of the targeted pathogen is high. 
Another study by Udy et al. analyzed the trough concentrations of multiple beta-lactams in a 
cohort of critically ill patients considered at risk of augmented renal clearance.57  The mean 
CLCR for this patient cohort was 134 ml/min/1.73m
2 with only 58% of patients maintaining a 
trough antibiotic concentration above the MIC. When a high PK/PD target of 4 x MIC was 
used, the proportion of patients achieving target concentrations fell to 31%. Although the 
PK/PD target for optimal therapeutic outcomes is still unclear, the above examples suggest 
that augmented renal clearance is an important contributor to sub-therapeutic dosing of beta-
lactam antibiotics. 
 
1.4.2.2 Renal replacement therapy 
Up to 5% of critically ill patients suffer from severe acute kidney injury, and of those, 70% 
would require RRT.58  Multiple variables, including altered plasma protein binding, dose and 
mode of RRT being used,59, 60 and the disease process itself ,61 can alter the PK of beta-
lactams.62  For example, significant increases in the clearance of meropenem were observed in 
a cohort of critically ill septic patients receiving high-volume continuous venovenous 
hemofiltration, with the increase was found to be associated with the ultrafiltration flow 
rate.63  On the other hand, clearance of ertapenem in patients with acute kidney injury 
receiving extended daily dialysis was comparable with healthy volunteers and other critically 
ill patients without renal disease.  Thus, a standard dose was required to maintain adequate 
antibiotic exposure in this cohort of patients, although a dose reduction was recommended for 
patients undergoing intermittent haemodialysis.  Current recommended beta-lactams doses, 
including adjustments according to renal function as provided by manufacturers, are at times 
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inappropriate in critically ill patients receiving RRT,64 especially for covering less susceptible 
organisms such as P. aeruginosa and Burkholderia pseudomallei, and so patient and 
pathogen-specific doses are often needed.60, 63  Due to the pathophysiological dynamic, some 
authors suggested application of TDM in this setting.59, 65 
 
1.5 Beta-lactam protein binding  
Hypoalbuminaemia is common among critically ill patients66 and is a potential source of 
altered PK in beta-lactam antibiotics with high percentage of protein binding such as 
ceftriaxone, flucloxacillin and ertapenem.47, 67  Albumin, the predominant plasma protein that 
beta-lactams bind to, is a negative acute phase protein that is often reduced in critically ill 
patients.68  Hypoalbuminaemia can lead to decreased protein binding and can increase the 
unbound fraction of drugs. In this case, if there is normal to high renal function, increased 
antibiotic clearance is likely.56  Alterations in protein binding may have significant clinical 
implications, since antibiotic activity is dependent on the unbound concentration of drugs.  In 
a murine model, beta-lactam activities against Staphylococcus aureus was found to differ 
markedly and correlate directly with percentage of protein binding in mouse serum, even 
though the test antibiotics had the same in vitro activities against the organism.69  The effects 
of hypoalbuminaemia on beta-lactam PK have been highlighted in a number of studies 
including one from Brink et al, where exposure of unbound ertapenem, as measured by Cmax 
and AUC, was negatively correlated with plasma albumin concentration.47  In another study 
by Ulldemolins et al, a two-fold increase in Vd for total flucloxacillin concentrations was 
observed in critically ill patients with hypoalbuminaemia when compared to healthy volunteer 
data.70  When this data was subsequently interpreted in the context of unbound 
concentrations, the authors showed that a standard 2 g bolus dose was insufficient to attain 
PK/PD target for methicillin-susceptible S. aureus (MSSA).70   
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Whilst altered protein binding can affect the unbound drug concentration in blood, it is 
possible that this effect extends to the target site of infections which is most cases is the 
interstitial fluid of tissues.  In a hypoalbuminaemic state, an increase in the intravascular 
unbound antibiotic fraction theoretically allows higher amount of unbound drug to distribute 
into the interstitial fluid. It follows then that changes in protein binding would have a more 
pronounced influence on interstitial fluid concentration of antibiotics, particularly those with a 
high degree of protein binding.71  However, pathophysiological changes in critically ill 
patients could alter the interstitial fluid concentration of beta-lactam antibiotics in multiple 
ways, which might be difficult to predict. 
 
Studies that have attempted to define variations in interstitial fluid concentrations of beta-
lactams, not necessarily highly protein bound though, have demonstrated variability as well. 
For example, a significant reduction of piperacillin interstitial fluid concentrations was 
observed in critically ill patients that had undergone cardiac surgery as compared with data 
from healthy volunteers.72  In patients with septic shock, interstitial fluid concentrations of 
piperacillin were found to be up to 10-fold lower than corresponding unbound plasma 
concentrations.73  However, the significance of altered protein binding in relation to 
interstitial fluid drug concentrations of highly protein bound beta-lactams is yet to be 
determined. 
 
These observations highlight the potential importance of directly quantifying the active 
unbound concentrations of beta-lactams when evaluating the PK/PD outcome of empiric 
dosing in critically ill patients.  However due to technical challenges, the majority of PK/PD 
studies for beta-lactams are based on measures of total plasma antibiotic concentrations. 
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Subsequent calculation of unbound concentrations is then extrapolated from protein binding 
data obtained from non-critically ill patients and healthy volunteers.  Several calculation 
models have been developed to normalize drug concentrations in the presence of altered 
plasma protein binding, but their applicability for beta-lactams in critically ill patients is yet to 
be determined.74, 75  Given the potential benefit of optimizing beta-lactam dosing in critically 
ill patients, evaluation of an alternative assay method that directly measures unbound 
antibiotics concentrations in TDM is warranted.   
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Aims 
 
Overall Aim: 
To determine the total and unbound concentrations of selected beta-lactam antibiotics in 
critically ill patients, and apply these to existing PK/PD principles to determine clinical 
outcomes provided by TDM-guided dosing in critically ill patients.  
 
The specific aims of this research are: 
1. To apply two validated high-performance liquid chromatography (HPLC) assays 
measuring total and unbound plasma beta-lactams concentrations in a heterogeneous 
sample of critically ill patients, and to evaluate the predictive performance for 
calculating unbound concentrations using published protein binding values. 
2. To document the total and unbound PK beta-lactams in critically ill patients, and 
determine the clinical and demographic factors associated with altered antibiotic 
exposures. 
3. To document clinical cure, bacteriological cure and achievement of PD endpoints 
(fT>MIC and f T>4xMIC) in critically ill patients receiving empiric dosed beta-lactam 
antibiotic treatment with TDM guided dose adjustment. 
4. To determine the PK/PD indices associated with positive clinical outcome in critically 
ill patients with gram negative bacteraemia treated with beta-lactams. 
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Chapter 2  Contemporary application of therapeutic drug monitoring in antibiotics 
dosing in critically ill patients: Current evidence and practical 
considerations 
 
2.1  Synopsis 
The aim of this chapter is to systemically analyse the current literature describing the risk of 
inadequate drug exposure in critically ill patients and evaluate the role of TDM for different 
classes of antibiotics in this setting. This chapter specifically addresses available evidence 
relating to practices of antibiotic TDM, including that of beta-lactams, and the practical 
aspects of applying TDM to potentially improve outcomes from severe infections in the 
critically ill. 
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2.2 Published review article entitled, “How do we use therapeutic drug monitoring to 
improve outcomes from severe infections in critically ill patients?” 
 
The manuscript entitled, “How do we use therapeutic drug monitoring to improve outcomes 
from severe infections in critically ill patients?” has been accepted for publication by BMC 
Infectious Diseases (2014; 14(1):288) 
 
The co-authors contributed to the manuscript as follows: All literature review were performed 
by the PhD candidate, Gloria Wong, and Dr. Fekade Sime, under the supervision of Prof. 
Jason A. Roberts.  The PhD candidate, Gloria Wong, and Dr. Fekade Sime, were responsible 
for data extraction from cited articles. Analysis of data was performed by the PhD candidate, 
Gloria Wong, and Dr. Fekade Sime, under guidance of Prof. Jason A. Roberts and Prof. 
Jeffrey Lipman. The PhD candidate, Gloria Wong, took the leading role in manuscript 
preparation and writing. 
 
The manuscript is presented as published, except figures and tables have been inserted into 
the text at slightly different positions. Also, the numbering of pages, figures and tables has 
been adjusted to fit the overall style of the Thesis. The references are found alongside to the 
other references of the Thesis, in the section ‘Reference’. 
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2.2.1 Abstract 
High mortality and morbidity rates associated with severe infections in the critically ill 
continues to be an significant issue for the healthcare system.  In view of the diverse and 
unique pharmacokinetic profile of drugs in this patient population, there is increasing use of 
therapeutic drug monitoring (TDM) in attempt to optimize the exposure of antibiotics, 
improve clinical outcome and minimize the emergence of antibiotic resistance.  Despite this, a 
beneficial clinical outcome for TDM of antibiotics has only been demonstrated for 
aminoglycosides in a general hospital patient population.  Clinical outcome studies for other 
antibiotics remain elusive. Further, there is significant variability among institutions with 
respect to the practice of TDM including the selection of patients, sampling time for 
concentration monitoring, methodologies of antibiotic assay, selection of 
pharmacokinetics/pharmacodynamics (PK/PD) targets as well as dose optimisation strategies. 
The aim of this paper is to review the available evidence relating to practices of antibiotic 
TDM, and describe how TDM can be applied to potentially improve outcomes from severe 
infections in the critically ill.  
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2.2.2 Introduction  
Despite advances in contemporary medicine, severe infections and sepsis-related mortality in 
critically ill patients remains a global problem.3, 76-78  An important consideration of 
antimicrobial treatment failure in the critically ill is inadequate drug exposure from use of 
dosing regimens derived in non-critically ill patients.79  There is extensive evidence of sub-
therapeutic exposure from standard doses across different antibiotic classes including beta-
lactams,80, 81 aminoglycosides,82 glycopeptides,83 fluoroquinolones,84 and oxazolidinones.85 
This can be a direct consequence of pharmacokinetic alterations emanating from the complex 
pathophysiologic processes associated with severe infection. Multi-drug resistant organisms 
more frequently encountered in the critically ill also alter the dosing requirements for these 
patients.86-88  Appropriate, timely antibiotic therapy given at an adequate dose is thought to be 
of paramount importance in improving clinical outcome of severe sepsis.14  To further 
increase the likelihood of achieving a good patient outcome from infection optimizing 
antibiotic dosing is crucial.  Therapeutic drug monitoring (TDM), a tool traditionally used 
primarily to minimize toxicity in drugs with narrow therapeutic window or drugs with 
complex pharmacokinetics, is being increasingly used for antibiotic dose optimization in the 
attempt to improve attainment of pharmacokinetic/pharmacodynamic (PK/PD) targets and 
outcomes of severe infections in the critically ill.35, 89-91 
 
Despite a growth in practice of antibiotic TDM globally, clinical outcome studies on TDM-
based interventions are limited. To date, definitive benefit is only demonstrated for 
aminoglycosides.92, 93  Further, there is significant variability among institutions with respect 
to the practice of TDM including the selection of patients, sampling time for concentration 
monitoring, methodologies of antibiotic assay, selection of PK/PD target as well as dose 
optimisation strategies.94  The aim of this paper is therefore to critically review the available 
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evidence of the practices of antibiotic TDM, and describe how TDM can be utilised 
potentially improve critically ill patient outcomes from severe infections.   
 
2.2.2.1 Pharmacokinetic changes in the critically ill  
Altered pharmacokinetics of antibiotics in ICU patients with severe infections secondary to 
dynamic disease processes and medical interventions has been widely described.84, 85, 95, 96  
Altered drug exposure may also be observed in patients with severe sepsis outside the ICU. 
Specifically, changes in volume of distribution (Vd) and drug clearance (Cl) may lead to sub-
therapeutic or toxic exposures of antibiotics when standard doses are used.  Table 2.1 
describes common factors that may alter antibiotic pharmacokinetics of antibiotics in 
critically ill patients.  Fluid resuscitation, capillary leakage and third space losses could 
substantially increase Vd of hydrophilic antibiotics such as beta-lactams and aminoglycosides, 
the Vd of which approximates the extracellular fluid volume.  The Cl of antibiotics is 
dependent on patient organ function, drug clearance mechanisms and extracorporeal 
interventions given to the patient.  Renal hypoperfusion, acute kidney injury and end-organ 
failure decrease Cl of antibiotics. On the contrary, augmented renal clearance (ARC) has been 
described in critically ill patients, where increased elimination of antibiotics lead to sub-
therapeutic concentrations.57, 97  The impact of interventions such as renal replacement 
therapy (RRT) and extracorporeal membrane oxygenation (ECMO) on antibiotic 
pharmacokinetics is multifactorial, variable and complex and have been discussed in detail 
elsewhere.62, 98-100  
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Table 2.1. Summary of common factors associated with altered pharmacokinetics of 
antibiotics in critically ill patients 
Increased Vd  Decreased Cl  Variable changes in Vd and/or Cl 
Hypoalbuminaemia, leading to 
increased unbound drug 
Renal hypoperfusion Extracorporeal interventions (eg 
RRT, ECMO) 
Capillary leakage Acute kidney injury  
Fluid resuscitation Renal/ hepatic dysfunction  
Third space loss   
 Increased Cl  
 Augmented renal clearance  
 
2.2.2.2 Main Pharmacokinetic/Pharmacodynamic Indices Associated with Antibiotic 
Efficacy 
The three main PK/PD indices that describe antibiotic exposure required for bacterial stasis or 
killing are summarised in Table 2.2a and 2.2b.  The PK/PD targets for individual groups of 
antibiotics proven or proposed to be associated with clinical advantage based on animal and 
clinical studies are also listed.  Of note, all PK/PD targets are expressed in relation to the 
minimal inhibitory concentration (MIC) of the pathogen, highlighting that beyond 
measurement of antibiotics concentrations, accurate and timely determination of MIC also 
should be considered a cornerstone of antibiotic TDM.  MICs for TDM can be defined by 
various strategies, including Epsilometer test (Etest), disc method, micro-dilution broth 
method and automated microbiology system (e.g. Phoenix, Vitek 2), or adoption of local 
antibiograms, European Committee on Antimicrobial Susceptibility Testing (EUCAST) and 
Clinical and Laboratory Standards Institute (CLSI) breakpoints. Clinicians utilising TDM in 
treating severe infections, especially those that involve resistant organisms, need to be aware 
of the limitations of each method. These limitations have been discussed in detail 
elsewhere.101-105 
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Table 2.2a.  Summary of time-dependent antibiotics and proposed targets for TDM dose adjustments. 
 PK/PD Indices Antibiotics PK/PD thresholds associated with optimal bacterial 
killing and/or clinical outcome 
PK/PD threshold for potential toxicity 
Time-dependent fT>MIC Beta-lactams   Predominantly 100% fT>MIC for TDM purposes94 Has not been clearly defined.  Thresholds from 
100% fT>6xMIC to 100% fT>10xMIC has been 
arbitrarily chosen by some centres94 
penicillins 30% fT>MIC (bacteriostatic) 
50% fT>MIC (bactericidal – animal model and 
clinical studies in non-critically ill patients)106  
cephalosporins 40-70% fT>MIC (animal models)106, 107 
100% fT>MIC up to 100% fT>4-5xMIC (optimal clinical 
outcome observed for cefepime and ceftazidime)35, 
108  
carbapenems 20% fT>MIC (bacteriostatic) 
40% fT>MIC (bactericidal) 
100% fT>5xMIC (optimal clinical outcome observed 
for meropenem)109  
monobactams 50% fT>MIC (bactericidal)  
Linezolid >85% fT>MIC110, 111  
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Table 2.2b.  Summary of concentration-dependent with time-dependence and concentration-dependent antibiotics, and proposed targets for 
TDM dose adjustments. 
 PK/PD Indices Antibiotics PK/PD thresholds associated with optimal bacterial 
killing and/or clinical outcome 
PK/PD threshold for potential toxicity 
Concentration-
dependent with 
time-
dependence 
AUC0-24/MIC 
(AUIC) 
Vancomycin 
 
 
 
a) AUIC ≥ 400 (corresponds to trough 
concentrations of 15–20 mg/Lfor intermittent 
dosing; trough of 20-25 mg/L for continuous 
dosing)  
b) trough concentrations >10 mg/L to avoid 
development of resistance89 
Trough concentrations >27 mg/Lwith intermittent 
dosing  
Linezolid AUIC > 80 to 120 (corresponds to trough 
concentrations > 2mg/L)110, 111  
Has not been clearly defined.  
Theoretical maximum trough concentrations 
threshold: 7-10 mg/L112-114 
Recommended maximum: 7 mg/L114 
Fluoroquinolones AUIC > 125 for Gram negative organisms115-117   
Aminoglycosides Relation to therapeutic efficacy mainly shown in 
animal infection models  
 
Daptomycin AUIC > 666118 Trough concentrations >24.3 mg/L119 
Concentration-
dependent 
Peak (Cmax)/ MIC Fluoroquinolones Cmax/MIC >10 prevent emergent of resistant 
mutants in in vivo and in vitro models115, 120, 121 
 
Aminoglycosides Cmax/MIC 8-10 122 High dose extended-dosing: troughs 
undetectable or <1 mcg/mL 
Daptomycin Cmax/MIC 59-94123  
Abbreviations:  fT>MIC, percentage/ fraction of dosing interval during which unbound antibiotic concentration remain above the MIC of targeted bacteria; AUC0-24/MIC, ratio 
of the area under the concentration–time curve (AUC) of the unbound drug from 0–24 hour and the MIC of targeted bacteria; Peak (Cmax)/ MIC, ratio of the peak 
concentration during a dosing interval and the MIC of targeted bacteria 
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2.2.3 How TDM could be utilised to optimize PK/PD in treating severe infections – 
clinical evidence and practical issues 
 
2.2.3.1 Beta-lactams 
Given the excellent safety profile of beta-lactams, the main aim of TDM with these antibiotics 
is to maximise efficacy through achievement of therapeutic exposures.124  Targets required to 
achieve a favourable clinical outcome in the critically ill have been described to be higher 
than that supported by studies in animal models or in non-ICU patients (Table 2.2a).  A 
PK/PD target of 100% fT>MIC as against fT>MIC lower than 100% was associated with 
significantly greater clinical cure and bacteriological eradication in septic critically ill patients 
with bacteraemia, lower respiratory tract or complicated urinary tract infection treated with 
cefepime and ceftazidime.35  Tam et al found similar associations against gram-negative 
infections, although proposed an even higher PK/PD target with cefepime (on concurrent 
aminoglycosides).108  Unfortunately, achievement of these higher drug concentrations in ICU 
patients is infrequent, especially in the early phase of sepsis.80, 125  Other dosing strategies 
have been proposed for optimizing beta-lactams exposure, these include dose adjustments 
made specific to interventions, continuous infusion and dosing monograms.  However, 
individual reports still demonstrate the extreme difficulties in achieving appropriate drug 
concentrations in some severely ill patients.62, 126-129  TDM appeared to be a feasible strategy 
to adapt beta-lactam dosing and may complement these other measures.86, 130  The potential 
benefit of beta-lactam TDM probably warrants evaluation of its value for treating severe 
infections in the critically ill, despite the fact that the optimal PK/PD target remains unclear. 
 
Beta-lactams have a low likelihood of toxicity.  However, given the high drug concentration 
requirement in some severely ill patients for difficult to treat infections, toxicity becomes an 
  24 
issue that could be minimize with TDM.  No threshold of toxicity has been defined currently, 
however TDM could aid early recognition of potential drug-related toxicities (especially 
neurological toxicity) in susceptible patients.131-133 
 
Selection of patients 
Patients with sepsis or septic shock, who potentially would benefit from TDM, are those with 
labile blood pressure (ie septic shock), dynamic renal function, burns injury, receiving RRT or 
ECMO, infected with resistant organisms, and where neurological toxicity is clinically 
suspected.94, 134, 135 
 
Sampling time 
Trough concentrations sampled at steady state (generally after 3-4 doses given) are 
appropriate for determining whether PK/PD targets have been achieved.  Additional sampling 
(e.g. at mid-dosing interval) is appropriate for a more accurate calculation of pharmacokinetic 
parameters and would be useful for a Bayesian-driven dose adaptation using appropriate 
computer software.   
 
Assay 
Liquid chromatography is the most widely used assaying method for beta-lactam TDM136-140.  
A variety of published protocols are available to suit clinical and laboratory needs in different 
institutes.94  The high equipment and personnel costs as well as the relatively prolonged 
processing time (between 6-24 hours) are disadvantages of the method that might hinder the 
wider application of beta-lactam TDM.  Direct measurement of unbound drug concentrations 
is also recommended in critically ill patients with hypoalbuminaemia receiving highly 
protein-bound antibiotics.141   
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Dose adjustment strategies 
Generalized but non-specific dose adjustment methods including changing dose amount or 
frequency, utilization of extended or continuous infusion have been used in most units 
practising TDM routinely.94  New dosages can be determined more accurately by calculating 
the individual patient’s drug clearance from measured beta-lactam concentrations.  Dosing 
nomograms and PK softwares for dose adjustment are available but have not been widely 
tested nor validated.126, 142 
 
2.2.3.2 Aminoglycosides 
With activity against gram-negative bacteria, aminoglycosides are an inexpensive group of 
antibiotics frequently used in the ICU for treatment of severe infections.  Once-daily 
administration to maximize its concentration-dependent effect and post-antibiotic effect is 
widely accepted as the standard regimen in general ward patients, and in ICU patients as well.  
For gentamicin, the regimen itself has been proven to provide small improvement in efficacy 
and/or reduced nephrotoxicity, and the benefit is augmented with active TDM.91, 143-146  
Gentamicin, tobramycin and amikacin are the three antibiotics mostly subjected to TDM.  In 
non-critically ill patients, the aim of TDM for extended interval aminoglycoside dosing is 
mainly to reduce toxicity, as arguably the single high dose would provide an adequate Cmax 
(maximum concentration in dosing interval) in most cases.147  However, these doses in 
critically ill patients are associated with a decreased rate of achievement of peak and AUC 
(area under the concentration-time curve) targets.82, 148-151  Although minimizing the 
likelihood of toxicity using TDM is important in critically ill patients, dose adaptation to 
avoid under-dosing and maximize efficacy is also valuable.   Given the high mortality rate of 
severe infections in the critically ill, high variability in aminoglycoside PK, and the proven 
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benefit of aminoglycoside TDM in general patient populations, TDM practice tailored to the 
critically ill population is advised. 
 
Selection of patients 
Measurement of Cmax concentrations is advisable in patients with conditions associated with 
an increased Vd (eg. burns, septic shock).  Those with unstable hemodynamic and/or renal 
function, undergoing RRT, infected with resistant pathogens would also benefit from routine 
TDM. AUC based monitoring is preferred, but where not possible, trough concentration 
monitoring to minimize toxicity is suggested especially for patients receiving regimens 
exceeding 48 hours.152-155 
 
Sampling time 
Traditionally, measuring one random concentration between 6-14 hours after commencement 
of antibiotic infusion with interpretation using a nomogram has been used for 
aminoglycosides. Given these nomograms are more commonly developed in non-critically ill 
patients, use of this approach in the critically ill is not recommended.144, 156  TDM with two 
samples drawn at 1 (30-mins post completion of drug infusion) and 6-22 hours post 
administration157, 158 allows description of peak concentrations and AUC using linear 
regression or Bayesian approaches and a more accurate prediction of future dosing 
requirements. 
 
Assay 
Commercially available immunoassays are the most frequently used method for 
aminoglycoside TDM.  Although other methods such as capillary zone electrophoresis and 
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chromatography offer higher precision, the inexpensive immunoassays have been validated 
and are appropriate for routine daily clinical practice.159, 160 
 
Dose adjustment strategies  
The PK/PD targets conventionally used for aminoglycoside TDM are described in Table 2.2b.  
To the best of our knowledge, no other targets have been established especially for the 
critically ill population. Calculation of the AUC for an individual patient and subsequent 
dosage adjustment using dosing software should be considered the ideal.  Although clinical 
advantages of using dosing software based methods have not been demonstrated, they should 
be considered preferred for critically patients with severe infections.161-163 
 
2.2.3.3 Vancomycin  
The benefit of vancomycin TDM both for avoidance of toxicity as well as improving clinical 
outcome remains controversial. Conflicting evidence exists in regards to correlation of 
nephrotoxicity with high serum vancomycin concentrations.164-171 A recent meta-analysis 172 
concluded that the collective literature favours the association. However it is still debatable 
whether the high concentration or kidney damage is the preceding event.  Similarly 
controversy exists with respect to ototoxicity173, 174 as well as benefit in clinical outcome.90, 171, 
175-177 A meta-analysis by Ye et al 178 suggested TDM significant increases in the likelihood of 
clinical efficacy and decreases the rate of nephrotoxicity. There is also a good agreement in 
the benefit of TDM to prevent the emergence of vancomycin resistant organisms with trough 
concentration above 10 mg/L.177, 179, 180   
 
Selection of patients 
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TDM is warranted to avoid toxicity in patients receiving high doses; during concomitant 
therapy with other nephrotoxic or ototoxic agents, in patients with unstable renal function, 
those receiving prolonged therapy (> 3 to 5 days), during RRT and in hemodynamically 
unstable critically ill septic patients.89, 181 
 
Sampling time 
Trough concentrations are modestly correlated with AUC enabling prediction of the target 
AUC/MIC.182, 183  Based on available techniques, samples should be taken at pharmacokinetic 
steady state, which would usually be before the fourth dose (assuming 12-hourly dosing).184 
In patients with renal dysfunction where half life is prolonged, steady state may not be 
achieved at the fourth dosing and therefore trough a concentration at this time may 
underestimate steady-state antibiotic exposure.184, 185  This should be taken into consideration 
when making any dose adjustment. 
  
 
Assay 
Immunoassay is the most widely used commercial assays.186  Currently there is no data 
indicting the superiority of any of the immunoassay methods over the others.187  However, 
bias due to lack of between-method standardisation and high variability of measurement 
between methods is likely.188, 189  Immunoassays remain appropriate for daily clinical TDM.  
 
 
Dose adjustment strategies 
Dose adjustments can be made by proportionally increasing or decreasing the dose relative to 
the ratio of the measured and the target concentration. The target concentrations commonly 
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used for intermittent (15-20 mg/L) and continuous dosing (20-25 mg/L) are not the same with 
a higher continuous infusion target required to ensure the achievement of the same AUC as 
the intermittent dosing.  Methodologies for dose individualization based on calculation of 
individual pharmacokinetic parameters and PK/PD targets (AUC/MIC) are available but not 
widely adopted in clinical practice.190  Real time Bayesian forecasting coupled with TDM is 
thought to be most accurate for dose adaptation.191, 192  
 
No conclusive evidence supports the benefit of CI as a dose optimization strategy. It is not 
superior to intermittent dosing in terms of microbiological and clinical outcomes.193-198  It 
may be considered though as a faster means to achieve consistent therapeutic 
concentrations given an adequate loading dose is used to avoid initial sub-therapeutic 
exposure83, 199-201. A recent meta- analysis202 suggested a potential benefit of CI in reducing 
risk of nephrotoxicity. 
 
2.2.3.4 Linezolid  
The variability in linezolid pharmacokinetics was traditionally regarded less significant than 
with other antibiotics and consequently dose adjustments were considered unnecessary even 
in patients with renal and hepatic impairments.203  However, accumulation of linezolid in 
renal insufficiency has been shown to be likely and results in toxicities such as pancytopenia, 
thrombocytopenia and liver dysfunction.112, 204-206  Reduced clearance has also been suggested 
in moderate hepatic insufficiency.207  Contrasting reports exist on the possibility of disease 
related pharmacokinetic alterations.  Consequently standard doses may result in a variable 
pharmacodynamic exposure,208 and are reported in the critically ill population with burns 
injuries.209, 210  Elevated plasma concentration and associated risk of toxicity have also been 
reported.110, 211, 212  In general, data to date indicates that TDM may be required in about 30 to 
  30 
40% of patients to avoid dose-dependent toxicity as well as therapeutic failure.96, 208  The 
impact of linezolid TDM on clinical outcome is yet to be demonstrated.  
 
Selection of patients  
A universal TDM program for linezolid is not supported based on current clinical data. 
Critically ill patients with sepsis, burns, pleural and peritoneal effusions, organ failure; 
patients infected with multidrug resistant bacteria; those receiving concomitant therapy with 
drugs that alter linezolid concentrations as well as those receiving long term linezolid therapy 
may benefit from TDM.207, 212, 213   
 
Sampling time  
Trough concentrations are well correlated with AUC and are sufficient for linezolid TDM and 
estimation of an AUC/MIC ratio.208, 214 The initial TDM sample should be taken just after 
pharmacokinetic steady state is achieved (usually considered on the third day of therapy).  
 
Assay  
HPLC methods have been published for linezolid TDM in plasma,213, 215 dried plasma spots216, 
217 and oral fluid218 with good correlations between methods.   
 
Dose adjustment strategies  
Dose adjustments can be made by proportionally increasing or decreasing the dose in 
reference to the target concentration range (Table 2.2b).  CI may be a valuable strategy to 
provide a stable therapeutic exposure.  
 
2.2.3.5 Fluoroquinolones 
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Difficult-to-predict pharmacokinetics of fluoroquinolones, particularly ciprofloxacin, can 
occur in critically ill patients as well as other patient groups. TDM may be beneficial given 
this pharmacokinetic variability to avoid treatment failure as well as minimise the emergence 
of resistance, particularly in the presence of less susceptible pathogens such as Pseudomonas 
aeruginosa which may have MICs of >0.5 mg/L.93, 219, 220 
 
Ciprofloxacin accumulation necessitating dose reduction has been reported in non-critically ill 
patients with renal impairment,221 although Van Zanten et al84 argued that dose reduction is 
unnecessary in critically ill patients despite their observation of increased AUCs.  Other 
authors52, 115, 222 also do not support dose reduction since accumulation is generally rare. It is 
likely that in patients with renal and gastrointestinal failure that dose reduction will be 
required as both clearance mechanisms will be affected. However, factors such as significant 
extracorporeal clearance due to RRT could influence variability of concentration in the 
critically ill.223, 224 TDM may thus be an advantage for ciprofloxacin, although has yet to be 
described for levofloxacin or moxifloxacin.  
 
 
Selection of patients  
Universal TDM is not recommended and no specific patient groups have been shown to 
benefit most from TDM. Patients with infections caused by organisms with a high MIC (> 0.5 
mg/L) may benefit most, as traditional dosing is likely to result in sub-optimal exposure in 
high proportion of these patients.   
 
Sampling time 
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At least two samples (peak and trough) should be taken to estimate the AUC. Both of these 
samples should be measured at steady state. The peak should be sampled in the post 
distribution phase, i.e. at least 30 min from the end of bolus infusion.115  
 
Assay 
HPLC is the predominant method for measuring fluoroquinolones in plasma225, 226 with dried 
blood spots227 also used for TDM.  A method using capillary electrophoresis has also been 
described228 and immunoassay may be a more convenient future alternative.229  
 
Dose adjustment strategies  
A wide range of targets has been proposed (Table 2.2b), however AUC/MIC of 125 or a 
Cmax/MIC of 8-10 is mostly accepted for treatment of Gram negative pathogens.  A validated 
approach for dose adjustment is not currently available. Generally, to increase the AUC0-24, 
increasing the dose (e.g. IV 400mg to 600mg) or the frequency of dose (12-hourly to 8-
hourly) are the more common methods for dose adaptation.  
 
2.2.3.6 Daptomycin 
TDM data on daptomycin is limited. The high protein binding and variable renal clearance 
make daptomycin a plausible candidate for TDM to increase the likelihood of achieving 
PK/PD targets.107, 230, 231  TDM might also be useful in reducing the risk of musculoskeletal 
toxicity where it is highly associated with a trough concentration (Cmin) of >24.3 mg/L,
119 
especially when higher than standard doses are used.  Current data is probably not sufficient 
to support a systematic TDM program for daptomycin.  In vivo and small patient cohort 
studies reported efficacy cutoffs of AUC/MIC of 666 and Cmax/MIC of 59-94, the optimal 
PK/PD target for clinical application is yet to be elucidated.118, 123  However, critically ill 
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patients with sepsis, thermal burn injuries, profound hypoalbuminaemia, those infected by 
less susceptible bacteria, and those receiving RRT could potentially benefit from TDM-
guided therapy as a means of ensuring achievement of PK/PD targets.  Validated 
chromatographic assay methods are available for quantification of daptomycin,232 but given 
the high protein-binding of daptomycin and prevalence of hypoalbuminaemia in the critically 
ill, direct measurement of unbound drug concentrations might be preferred for clinical 
practice. 
 
2.2.4 Conclusion 
TDM has traditionally served as a mechanism to minimize the toxicity of drugs. However, the 
approach to use TDM to maximize the therapeutic effects of less toxic compounds is 
becoming increasingly common. In the context of critical illness, there is strong data 
demonstrating that standard dosing regimens for many antibiotics frequently fail to provide 
optimal PK/PD exposure in critically ill patients. Given that pharmacokinetic exposures can 
be very difficult-to-predict in some patients, TDM is valuable to identify these patients and 
guide dose optimization.  TDM can ensure attainment of PK/PD surrogate indicators of 
antibiotic efficacy, and therefore potentially improve patient outcome. A conservative 
approach to development of TDM programs is suggested because for many antibiotics, the 
personnel and resource costs are moderate and studies demonstrating conclusive clinical 
outcome advantages remain elusive. Based on the available data, a well-designed randomized 
controlled trial to determine the effect of TDM-guided dosing is supported.  
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2.3 Conclusion 
In this chapter, we summarized the theoretical and clinical evidence that support application 
of TDM for personalized antibiotic dosing in the critically ill, and the general approach for 
each antibiotic class.  We identified gaps in the current evidence; in particular desirable 
PK/PD targets related to positive clinical outcomes, given the most current practices are 
extrapolated from studies in animal and non-critically ill population.  Data on the impact of 
hypoalbuminaemia on unbound antibiotics PK is lacking as well.  Given the potential of TDM 
in improving clinical outcome in the critically ill, further characterization of TDM-guided 
dosing is warrant in terms of defining optimal PK/PD targets and sub-populations that would  
most benefit from the intervention.
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Chapter 3  Beta-lactam TDM: approaches used in critically ill patients 
internationally 
 
3.1  Synopsis 
The aim of this chapter is to report findings of a multicentre survey on the various approaches 
used for beta-lactam TDM in ICUs worldwide. This chapter specifically addresses the 
variability of PK/PD targets, assay types and antibiotics subject to beta-lactam TDM in 
practice. 
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3.2 Published article entitled, “An international, multi-centre survey of beta-lactam 
antibiotics therapeutic drug monitoring (TDM) practice in intensive care units” 
 
The manuscript entitled, “An international, multi-centre survey of beta-lactam antibiotics 
therapeutic drug monitoring (TDM) practice in intensive care units” has been accepted for 
publication by Journal of Antimicrobial and Chemotherapy (2013; 69(5):1416-23). 
 
The co-authors contributed to the manuscript as follows: All study design and data collection 
was performed by the PhD candidate, Gloria Wong, under the supervision of Prof. Jason A. 
Roberts. Analysis of data was performed by the PhD candidate, Gloria Wong, under the 
guidance of Prof. Jason A. Roberts, Prof Jeffrey Lipman, Dr Jan De Waele, and Dr Fabio 
Silvio Taccone. The PhD candidate, Gloria Wong, took the leading role in manuscript 
preparation and writing. 
 
The manuscript is presented as published, except figures and tables have been inserted into 
the text at slightly different positions. Also, the numbering of pages, figures and tables has 
been adjusted to fit the overall style of the Thesis. The references are found alongside to the 
other references of the Thesis, in the section ‘Reference’. 
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3.2.1 Abstract 
Objectives: Emerging evidence supports the use of therapeutic drug monitoring (TDM) of 
beta-lactams for intensive care unit (ICU) patients to optimize drug exposure, although 
limited detail is available on how sites practically run this service. This multi-centre survey 
study was performed to describe the various approaches used for beta-lactam TDM in ICUs.   
Methods: A questionnaire survey was developed to describe various aspects relating to the 
conduct of beta-lactam TDM in an ICU setting.  Data sought included: beta-lactams chosen 
for TDM, inclusion criteria for selecting patients, blood sampling strategy, analytical 
methods, pharmacokinetic/pharmacodynamic (PK/PD) targets and dose adjustment strategies.  
Results: Nine ICUs were included in this survey. Respondents were either ICU or infectious 
disease physicians, pharmacists or clinical pharmacologists. Piperacillin (co formulated with 
tazobactam) and meropenem (100% of units surveyed) were the beta-lactams most commonly 
subject to TDM, followed by ceftazidime (78%), ceftriaxone (43%) and cefazolin (43%).  
Different chromatographic and microbiological methods were used for assay of beta-lactam 
concentrations in blood and other biological fluids (e.g. CSF).  There was significant variation 
in the PK/PD targets (100% fT>MIC up to 100% fT>4xMIC) and dose adjustment strategies used 
by each of the sites.   
Conclusions: Large variations were found in the type of beta-lactams tested, the patients 
selected for TDM and drug assay methods.  Significant variation observed in the PK/PD 
targets and dose adjustment strategies used supports the need for further studies that robustly 
define PK/PD targets for ICU patients to ensure a greater consistency of practice for dose 
adjustment strategies for optimizing beta-lactam dosing with TDM. 
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3.2.2 Introduction 
 Therapeutic drug monitoring (TDM) is a commonly utilized dosing strategy to 
minimize toxicity and maximize the efficacy of drugs with a narrow therapeutic index. It is 
most commonly used when the pharmacokinetics (PK) and therefore the optimal dose of a 
drug for an individual patient is difficult to predict.  In clinical practice, the approach has been 
routinely used for many years for vancomycin and aminoglycosides, selected anticonvulsants, 
anticoagulants and antipsychotics.233 
 Beta-lactams are a family of antibiotics frequently prescribed in the setting of severe 
infection in intensive care units (ICU).  The indication may be for either empiric or directed 
therapy.  In the setting of the dynamic physiological changes that patients may undergo 
secondary to disease processes and clinical interventions, significantly altered beta-lactam PK 
is common.57, 70, 80, 133, 234, 235  Specifically, increases in volume of distribution (Vd) and 
dramatic fluctuations in drug clearance are common in critically ill patients, leading to sub-
therapeutic or toxic concentrations in large proportion of ICU patients when standard dosing 
strategies are used.81, 125 In view of the difficult-to-predict PK and the importance of early and 
appropriate antibiotic therapy in reducing mortality rates,8, 11-13, 236 TDM of beta-lactam 
antibiotics is increasingly being reported in critically ill patients.125, 237  The aim of beta-
lactam TDM is to provide doses of antibiotic that maintain unbound beta-lactam 
concentrations above bacterial minimum inhibitory concentrations (MIC) over a desired 
percentage of the dosing period (% fT>MIC).
35, 43, 238 
 The feasibility of performing beta-lactam TDM as a part of routine care in ICUs has 
been reported by various ICUs.125, 237, 239 Despite emerging evidence of the value of beta-
lactam TDM as a dose optimisation strategy in ICUs, there is limited information on how it is 
practically performed in the clinic.43, 86, 125, 130, 240   The aim of this paper is to describe in 
detail, the various approaches used for beta-lactam TDM in ICUs.   
  42 
3.2.3 Methods 
 A questionnaire survey was developed to describe various aspects relating to the 
conduct of beta-lactam TDM in an ICU setting.  The protocol items associated with practical 
implementation of beta-lactam TDM are listed in Table 3.1.  Contributing ICUs (or TDM 
units that perform TDM hospital-wide, including ICUs) were identified by a literature review 
of publications on beta-lactam TDM and from ICUs known by the investigators to be using 
TDM for beta-lactams in ICU patients.  Approval to conduct this low- and negligible- risk 
study was obtained from the Human Research Ethics Committee at the Royal Brisbane and 
Women’s Hospital, Australia (Ref: HREC/13/QRBW/243). 
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Table 3.1.  Beta-lactam TDM practice information collected in the survey.   
Beta-lactam TDM practice item surveyed Rationale 
Number of ICU beds and ICU type Demographic characteristics of ICUs that 
perform beta-lactam TDM 
Median number of TDM per day and per week 
Personnel who manage TDM programme 
Name of beta-lactams subject to TDM   
Inclusion and exclusion criteria  Criteria each ICU uses to select patients that 
will be subject to TDM 
Blood sample timing  Timing of blood samples during a dosing 
interval for measurement of beta-lactam 
concentrations 
Sampling of body fluids other than blood  Whether fluids other than blood are sampled 
for TDM  
Beta-lactams assay method Determine whether published methods are 
used to measure beta-lactam concentrations 
and whether total or free concentrations are 
measured 
Measurement of bacterial pathogen 
susceptibility  
How and under which circumstances MICs 
are determined (e.g. published susceptibility 
breakpoints, Vitek 2, and/or Etest)  
Time delay between sampling and availability 
of results to treating clinician 
 
PK/PD targets for dose adjustment 1. What therapeutic target is used? i.e. Which 
%fT>MIC is used 
2. Which is the PK/PD threshold of toxicity? 
Dose adjustments methods What strategies are used to adjust doses 
when concentrations are deemed too low or 
too high? 
Legend: TDM – therapeutic drug monitoring; ICU – intensive care unit; PK/PD – 
pharmacokinetic/pharmacodynamic; %fT>MIC – percentage that the free concentration of drug remains above the 
minimum inhibitory concentration of the pathogen 
 
Statistical analysis 
Data were subject to descriptive statistical analysis and are presented as proportion of ICUs 
(%) or mean (standard deviation) or median (IQR) as appropriate. 
 
3.2.4 Results 
3.2.4.1 Response rate and ICU demographics 
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 Nine of the 11 ICUs that were approached responded to the survey. The survey was 
completed by ICU physicians (n=3), infectious disease physician (n=1), clinical 
pharmacologist (n=1) or clinical pharmacists (n=4).  The characteristics and location of the 
participating ICUs included are listed in Table 3.2.  The majority of the ICUs are located in 
European countries (66.7%).   
Table 3.2. Details of the participating ICUs.  Data are listed as number (n), or median (IQR). 
Country n 
Australia 2 
Belgium 2 
France 1 
Germany 1 
Italy 1 
Switzerland 1 
USA 1 
ICU bed numbers 30 (15-35) 
ICU type  
Medical-surgical only 6 
Medical-surgical, with burns unit 
and/or other subspecialty units 
3 
 
3.2.4.2 Logistics of TDM program 
 The TDM programmes are primarily managed by ICU physicians (n=6), pharmacists 
(n=5), infectious disease physicians (n=3) and clinical pharmacologist (n=1), in conjunction 
with microbiologists and clinical biochemists depending on the nature of the clinical cases.  
The median number of days per week where TDM is available was 5 (IQR 4-5).  The median 
number of patients subject to TDM per day and per week ranged from 1 to 4 and from 1 to 15, 
respectively. 
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3.2.4.3 Beta-lactams subjected to TDM 
 The 21 beta-lactam antibiotics subject to TDM across the various ICUs are shown in 
Figure 3.1.  The number of beta-lactams monitored by a single centre ranged between 3 to 12 
(mean 7).  All ICUs included piperacillin (administered co-formulated with tazobactam) and 
meropenem for TDM. As shown in Figure 3.1, various cephalosporins were also frequently 
subjected to TDM. 
 
Figure 3.1.  Frequency that beta-lactam antibiotics were included as part of TDM program in 
surveyed ICUs. 
 
3.2.4.4 Inclusion and exclusion criteria 
 There was significant heterogeneity across the protocols for choosing which patients 
would be subject to beta-lactam TDM. The majority of the ICUs (n=5) specifically targeted 
TDM toward patients with severe sepsis or septic shock.  Other inclusion criteria were: 
specific types of serious bacterial infection requiring prolonged antibiotic treatment (eg. brain 
abscess, endocarditis, meningitis); impaired organ function (eg. renal impairment, assumed 
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augmented renal clearance (ARC),18, 57 liver failure/ cirrhosis); and patients undergoing to 
renal replacement therapy (RRT) and/or extracorporeal membrane oxygenation (ECMO).  
Other patient factors included immunosuppression, organ transplantation, severe burn injury 
and patient weight (underweight or obese).  Some ICUs performed TDM in the presence of 
multi-drug resistant pathogens, suspected beta-lactam toxicity and/or when beta-lactams were 
administered by continuous infusion.  
Three facilities also performed beta-lactam TDM in non-ICU patients who met one or 
more of the above criteria. Exclusion criteria included: (i) paediatric patients (age < 18 years) 
(n=7); (ii) patients whose beta-lactam antibiotic treatment was expected to be ceased within 
24 (n=2) and 72 hours (n=1) of sampling; (iii) prophylactic antibiotic use (n=1); (iv) 
concomitant antimicrobials with activity against the indicator organism of the microbiological 
assay (Staphylococcus epidermidis, Clostridium perfringens, or Klebsiella pneumoniae 
depending on the assay) (n=1). 
 
3.2.4.5 PK sampling timing 
 All protocols sampled trough concentrations of beta-lactams at assumed PK steady 
state when administered by intermittent dosing (steady state mostly defined as having been 
reached after four doses or 24 to 48 hours after onset of treatment). Sampling was performed 
at PK steady state when the antibiotic was given by a continuous infusion (frequently defined 
as four to five half-lives after commencement of therapy or after a dose change).  One ICU 
obtained an additional sample at 30% of the dosing interval.  Multiple samples [immediately 
after dosing, then 30% (or 40%), 50% and 70% of the dosing interval] were taken in two units 
for research purposes but not for dose adjustment calculations. Six ICUs also performed TDM 
in body fluids other than blood. Samples that could be subjected to TDM included CSF (n=5), 
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peritoneal fluid (n=4), RRT dialysate, urine, and rarely pleural effusion, bronchoalveolar 
lavage fluid, bile and joint aspirate. 
3.2.4.6 Beta-lactams assay methods  
 Microbiological assays were used in two units with chromatographic methods used 
elsewhere.  Among the facilities that used chromatography, two units measured total and/or 
unbound beta-lactam concentrations for TDM, while other ICUs measured total 
concentrations only.  The majority of the assay protocols were published (n=9, Table 3.3).  
Those that were not published were in-house protocols that had been validated by Valistat 2.0 
(Arvecon, Germany) or according to local regulatory guidelines.241, 242 HPLC with ultraviolet 
detection (HPLC/UV) was the predominant analytical system used (n=4), other systems used 
were ultra-performance liquid chromatography- tandem mass spectrometry (UPLC-MS/MS) 
and liquid chromatography–tandem mass spectrometry (LC-MS/MS).  Generally, antibiotic 
concentration results were available to treating clinicians within 6-12 hours from sampling 
time (when samples were received by the laboratories within scheduled hours) and up to 24-
48 hours in some facilities.   
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Table 3.3.  Published beta-lactam assay methods used by the surveyed facilities.   
Analytical 
system 
Antibiotics Calibration curve range, 
precision and accuracy 
Interval between 
sampling and 
availability of 
results†  
Reference 
Micro- 
biological 
assay 
amoxicillin/ clavulanic 
acid, cefazolin, 
cefepime, cefotaxime, 
ceftazidime, 
ceftriaxone, doripenem, 
ertapenem, imipenem, 
meropenem,  
piperacillin/ 
tazobactam, ticarcillin 
Calibration curve ranges 
chosen depending on 
antibiotics and test organism. 
Precision: ± 10 - 15% 
24 to 48 hours Kitzis 
(2010)105 
HPLC/UV aztreonam, cefepime, 
ceftazidime, 
cefuroxime, 
meropenem, 
piperacillin 
2 - 200 mg/L 
Precision: CV < 11% 
Accuracy: ± 30% 
12 hours (or 3 
days over 
weekend) 
Wolff et al 
(2013)243 
ampicillin, 
benzylpenicillin, 
cefalothin, cefazolin, 
ceftazidime, 
ceftriaxone,  
dicloxacillin, 
ertapenem, 
flucloxacillin, 
meropenem,  
piperacillin, ticarcillin 
1 – 500 mg/L  
(except meropenem 1 – 250 
mg/L) 
Precision: CV < 10% 
Accuracy: ± 6% 
Within 12 hours McWhinney 
et al 
(2010)139 
ampicillin, 
benzylpenicillin, 
cefalothin, cefazolin, 
ceftriaxone, 
dicloxacillin, 
ertapenem, 
flucloxacillin, 
meropenem, 
piperacillin  
*Unbound antibiotics: 
0.1 - 50 mg/L 
(except piperacillin 0.1 – 100 
mg/L) 
Precision: CV < 9.4% 
Accuracy: ± 15% 
Within 12 hours Briscoe et al 
(2012)140 
meropenem 3 – 50 mg/L 6 hours Bias et al 
(2010)244 
ceftazidime 1 – 200 mg/L 
Precision: CV < 6.2% 
Accuracy: 97.5 – 105.5% 
Within 6 hours Hanes et al 
(1998)245 
HPLC meropenem 10 – 70 mg/L 
LOQ: 12.85 μg/L 
Precision: CV < 0.85% 
Accuracy: 99.1 – 100.1% 
Within 6 hours Mendez et 
al (2003)138 
UPLC-
MS/MS 
amoxicillin, 
ampicillin, cefazolin, 
0.5 – 100 mg/L  
(except piperacillin 1.5 – 100 
6 hours Carlier et al 
(2012)136 
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cefuroxime, 
ceftazidime, clavulanic 
acid, meropenem, 
piperacillin,  
tazobactam 
mg/L) 
Precision: 10 - 20% at 
LOQ, 3 - 15% at higher levels 
Accuracy: 86.8 - 101.5%. 
LC-
MS/MS 
ampicillin, cefazolin, 
cefepime, 
cefmetazole, 
cefotaxime, doripenem, 
meropenem, 
piperacillin 
0.1 – 50 mg/L 
(except doripenem 0.5 – 50 
mg/L) 
Precision: CV < 14.6% 
Accuracy: 86.4 – 112.3% 
Within 6 hours Ohmori et 
al (2011)137 
† Limited to samples received by the laboratories before scheduled cut-off times on days that TDM was 
available 
*Concentrations of unbound (free) beta-lactam antibiotics were directly measured 
 
3.2.4.7 Determination of bacterial susceptibility  
 Two ICUs measured bacterial MICs routinely for TDM by micro-dilution broth 
method and the Phoenix Automated Microbiology System (BD Diagnostic Systems, Sparks, 
MD), respectively.  For others, MICs were measured by disc method, Etest (bioMérieux, 
France) or micro-dilution broth method only when the pathogen was determined to be 
intermediately susceptible to the antibiotic or where resistance to the prescribed antibiotic was 
demonstrated by Vitek 2 system testing (bioMérieux, France). Surveyed ICUs adopted 
EUCAST (n=8) or CLSI (n=1) breakpoints to determine PK/PD targets when MICs were not 
measured. Two of the ICUs also reported using a local hospital antibiogram data to describe 
likely pathogen susceptibility. 
 
3.2.4.8 PK/PD targets for dose adjustment 
 A minimum of 100% fT>MIC was adopted as the PK/PD target for dose increase by six 
of the ICUs. Dose reduction was undertaken mostly made on a case-by-case basis by all units 
when toxicity (especially neurological) was suspected or concentrations were above locally 
defined threshold concentrations for potential toxicity.  Six other targets for dose increase 
were described as shown in Table 3.4.  Only four units would reduce dose if concentrations 
were above the recommended PK/PD targets of efficacy. 
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Table 3.4.  List of PK/PD targets for dose adjustment adopted by selected ICUs. 
 PK/PD targets Specific conditions  
For dose increase 100% fT>MIC (n=5)  
100% fT2-4xMIC (n=1)  
50% fT>4xMIC (n=1) Intermittent bolus dosing 
100% fT>4xMIC (n=2) Continuous infusion 
40% f T>4xMIC (n=1) For meropenem 
50% fT>4xMIC (n=1) For piperacillin, aztreonam and 
cefuroxime 
70% fT>4xMIC (n=1) For cefepime and ceftazidime 
Threshold of 
potential toxicity for 
dose reduction 
100% fT10xMIC (n=4)  
100% fT8xMIC (n=1) MIC of Pseudomonas 
aeruginosa for the antibiotic 
100% fT6xMIC (n=1) Continuous infusion 
100% fT4-5xMIC (n=1) In the presence of susceptible 
pathogens  
Steady state concentration exceeding 2 
times of maximum exposure expected in 
general population. e.g. piperacillin > 100 
mg/l (> 32g/24 h in normal patient), 
meropenem > 32 mg/l (> 12g/24 h in 
normal patient) (n=1) 
Continuous infusion 
 
3.2.4.9 Method of dose adjustment 
 All ICUs adjusted the dose as soon as results became available. Only two ICUs 
determined a new dosage by calculation of the individual patient’s drug clearance from 
measured beta-lactam concentrations. Other ICUs adopted more generalized dose adjustment 
methods as summarised in Table 3.5. All except one of the ICUs increased the dose based on 
beta-lactam concentrations, susceptibility of the clinical isolate and the nature of infection, 
without a definite maximum dose per day for any specified antibiotic. Eight units performed 
follow up TDM. This was done regularly after dose adaptation (generally in every 24 – 48 
hours), after dose changes or if changes in a patient's characteristics were anticipated to alter 
beta-lactam PK. 
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Table 3.5.  Methods for dose adjustment based on initial mode of drug administration. 
 Dose adjustment strategy 
Dose increase: Increase dose administration frequency by 25 - 50% 
25 - 50% increased dose with same frequency 
Change to extended infusion (if concentration within 20% of the target) 
Change to continuous infusion (if at maximum daily dose per product 
information) 
Dose reduction: Decrease frequency of administration at the same dose 
25 - 50% decrease in dose with same dosing frequency 
Withhold therapy for one day  
 
3.2.5 Discussion 
 This is the first multi-centre survey to describe the clinical practice of beta-lactam 
TDM in an international selection of ICUs that currently use TDM for clinical purposes.  This 
report demonstrates the variation in beta-lactam TDM practice, especially in selection of beta-
lactams and patient population for TDM, drug assay methods, PK/PD targets and dose 
adjustment strategies.  Despite quite significant variations in practice, the general steps that 
pertain to beta-lactam TDM, can be summarised as illustrated in Figure 3.2.   
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Figure 3.2. General process between participating sites for application of beta-lactam TDM. 
 
 The list of beta-lactam antibiotics for TDM in each ICU varied, likely due to 
differences in the availability of beta-lactams in different countries, hospital formulary, 
prescribing habits, case-mix of patients and the pattern of bacterial susceptibility.246-252 
Piperacillin, meropenem, ceftazidime, ceftriaxone and cefazolin were subjected to TDM in 
the majority of the ICUs surveyed.  This finding is consistent with their high prevalence of 
usage2, 247, 249 and variable PK that has previously been published in critically ill patients.41, 51, 
56, 63, 86, 253-256 Despite an increasing amount of PK data in critically ill patients, the variability 
in the inclusion criteria for TDM may reflect the lack of robust dosing data.   
 A range of validated chromatographic beta-lactam assays were most commonly used 
for TDM.  All assays were reported to meet regulatory limits of accuracy and precision, with 
calibration curve concentration ranges that are clinically appropriate.  However, some assays 
have a relatively high limit of quantification (LOQ) (3 and 10 mg/L for meropenem). 
Although a high LOQ will not cause under-dosing in practice, it may result in unnecessarily 
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high antibiotic exposures in some patients infected by highly susceptible bacteria.  Of note, 
only two ICUs directly measured the unbound concentrations of beta-lactams.  Given that the 
unbound concentration of beta-lactams is responsible for bacterial killing, and 
hypoalbuminaemia occurs in approximately 40% of critically ill patients,66, 68 measuring total 
concentrations only may lead to under- or over-estimation the unbound concentrations and 
may jeopardize the accuracy of the method, especially for highly protein bound antibiotics.141 
Most assays are efficient and provide a same-day turn-around for results; however, the 
availability of TDM was still limited to certain hours and days of the week in some facilities. 
The chromatography technique used is associated with a high equipment and personnel costs, 
which might theoretically affect the cost-effectiveness of beta-lactam TDM. Microbiological 
assays performed by some units are an alternative to chromatography with comparable 
precision and robustness that could overcome the disadvantages of chromatography in terms 
of cost.105  However, its processing time is comparatively much longer. Interference of 
concomitant antibiotics with indicator bacteria also limits the use of bioassay in clinical 
practice. 
 Only two of the ICUs surveyed routinely measured bacterial MICs for beta-lactam 
TDM.  Although other units reported measuring MICs by Etest or Vitek 2 where deemed 
necessary, the majority of ICUs used local antibiograms or EUCAST breakpoints to 
determine MIC for PK/PD targets for most patients. Whilst useful for most clinical situations, 
the reporting of EUCAST breakpoints by microbiology laboratories is mostly of a categorical 
nature (susceptible, intermediate or resistant), only providing the upper MIC threshold for 
each categorisation, leading to a high target dose that is unnecessary for more susceptible 
pathogens.  In addition, factors used for determination of breakpoints are dynamic, and the 
predictive value of breakpoints might not hold when the bacterial epidemiology changes or 
new resistance mechanism emerges.   
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 Although the majority of ICUs adopted 100% fT>MIC as a PK/PD threshold for dose 
increase, targets for beta-lactam TDM remain diverse.  In vitro and animal studies 
demonstrated that the PK/PD targets of fT>MIC of 35–40%, 30% and 20% are bacteriostatic for 
cephalosporins, penicillins and carbapenems, respectively; whilst 40% fT>MIC for 
carbapenems, 50% for penicillins and monobactams, and 60-70% for cephalosporins are 
required for maximum bactericidal effect.5, 9, 37, 106  However, more aggressive PK/PD targets 
have also been suggested. In a study of critically ill patients with bacteraemia and sepsis 
treated with cefepime and ceftazidime, 100% fT>MIC was associated with significantly greater 
clinical cure and bacteriological eradication than patients with fT>MIC lower than 100%.
35  
Similar data were found by Tam et al,108 except for a higher PK/PD target with cefepime. The 
most significant predictor of successful clinical and microbiological responses was 
determined to be the fCmin/MIC ratio of 5 in a study of meropenem PD in patients with lower 
respiratory tract infections.109  A similar target was suggested in an in vitro PK model of 
ceftazidime against Pseudomonas aeruginosa by Mouton and den Hollander comparing 
effectiveness of intermittent and continuous beta-lactam infusion.42  In view of the varied 
information available in the literature, the variation in clinical practice we observed is not 
unexpected, although PK/PD targets selected by individual ICUs all cited published literature, 
albeit different literature.  Similar uncertainty in defining potential toxicity threshold was 
observed, which is consistent with the scarcity of published data on this topic.131, 257, 258  These 
observations also support the need for further studies that robustly define PK/PD targets for 
beta-lactam TDM.   
 Apart from two ICUs that calculated individual PK parameters for each new dosing 
regimen, the strategies for dose adjustment reported were quite non-specific.  Other 
approaches to dose adjustment were not necessarily widely use or available. The availability 
of nomograms for beta-lactam dosing is limited.126 PK software could also be applied to more 
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accurately define therapeutic doses, although such software has not been widely tested or 
validated.259   In addition to rapid achievement of therapeutic concentrations, accuracy and 
appropriateness of dose adjustment are needed to maximize the advantages that beta-lactam 
TDM could provide, as is the case when TDM is applied to any antibiotic.95, 183, 260 
 
3.2.5.1 Limitation of the study 
 The differences in clinical environment, antibiotic usage strategies between 
institutions, and the small sample of ICU populations limit the generalizability of our 
findings.  Data collection by convenience sampling may also introduce a selection bias, 
although the response rate was high and we are unaware of other centres also performing 
beta-lactam TDM at the time of the survey.  Nevertheless, such a bias is probably unavoidable 
with limited number of centers around the world known to be performing TDM routinely, and 
this study is the largest representation of ICUs adopting this strategy in beta-lactam antibiotic 
dosing. 
 
3.2.6 Conclusion 
 This is the first paper describing the practice strategies used by ICUs that perform 
beta-lactam antibiotic TDM as part of routine clinical care.  We found large variations in the 
beta-lactams tested as well as the patients selected for TDM, drug assay methods and dose 
adjustment strategies.  In particular, this survey highlights the controversies that apparently 
exist relating to the question of which PK/PD targets should be used in critically ill patients. 
We await robustly designed randomised controlled trials to address this present gap in the 
literature.  
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3.3  Conclusion 
In this chapter, we described the significant variability in beta-lactam TDM practice in 
clinical settings, despite the same underlying principle for the applying the process.  We 
identified some barriers to a unifying TDM practice, namely variable service availability in 
terms of beta-lactams assay and bacterial MIC measurement, which are both cost- and labour-
intensive; and lack of robustly defined PK/PD target and dose adjustment strategy applicable 
to the critically ill.  Nevertheless, this chapter provides a practical framework for future 
adoption of beta-lactam TDM practice in routine clinical practice, and identifies the gaps in  
literature in this topic.
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Chapter 4  The impact of variations in protein binding on prediction of unbound  
beta-lactam concentrations for TDM in the critically ill 
 
4.1  Synopsis 
The aim of this chapter is to describe a study comparing the directly measured and calculated 
unbound beta-lactam concentrations for TDM in the critically ill.  The predictive performance 
of the conventional method of calculating unbound beta-lactam concentrations using 
published protein binding values was determined. 
  59 
4.2 Published article entitled, “Protein binding of beta-lactam antibiotics in critically 
ill patients: can we successfully predict unbound concentrations?” 
 
The manuscript entitled, “Protein binding of beta-lactam antibiotics in critically ill patients: 
can we successfully predict unbound concentrations?” has been accepted for publication by 
Antimicrobial Agents and Chemotherapy (2013; 57(12):6165). 
 
The co-authors contributed to the manuscript as follows: All study design and data collection 
was performed by the PhD candidate, Gloria Wong, under the supervision of Prof. Jason A. 
Roberts. Analysis of data was performed by the PhD candidate, Gloria Wong, under the 
guidance of Prof. Jason A. Roberts and Prof Jeffrey Lipman. The PhD candidate, Gloria 
Wong, took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published, except figures and tables have been inserted into 
the text at slightly different positions. Also, the numbering of pages, figures and tables has 
been adjusted to fit the overall style of the Thesis. The references are found alongside to the 
other references of the Thesis, in the section ‘Reference’. 
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4.2.1 Abstract 
 The use of therapeutic drug monitoring (TDM) to optimize beta-lactam dosing in 
critically ill patients is growing in popularity, although there are limited data describing the 
potential impact of altered protein binding on achievement of target concentrations.  The aim 
of this study was to compare the measured unbound concentration to the unbound 
concentration predicted from published protein binding values for seven beta-lactams using 
data from blood samples obtained from critically ill patients.  From 161 eligible patients, we 
obtained 228 and 220 plasma samples at the midpoint of dosing interval and trough, 
respectively, for ceftriaxone, cefazolin, meropenem, piperacillin, ampicillin, benzylpenicillin, 
and flucloxacillin. The total and unbound beta-lactam concentrations were measured using 
validated methods.  Variability in both unbound and total concentrations were marked for all 
antibiotics, with significant differences present between measured and predicted unbound 
concentrations for ceftriaxone and for flucloxacillin at the mid-dosing interval (p<0.05).  The 
predictive performance for calculating unbound concentrations using published protein 
binding values was poor, with bias for under-prediction of unbound concentrations for 
ceftriaxone (83.3%), flucloxacillin (56.8%), and benzylpenicillin (25%) and over-prediction 
for meropenem (12.1%).  Linear correlations between the measured total and unbound 
concentrations were observed for all beta-lactams (R2 = 0.81 – 1.00, p<0.05) except 
ceftriaxone and flucloxacillin. The percentage protein binding of flucloxacillin and plasma 
albumin concentration were also found to be linearly correlated (R2 = 0.776, p<0.01).  In 
conclusion, significant differences between measured and predicted unbound drug 
concentrations were found only for the highly protein bound beta-lactams ceftriaxone and 
flucloxacillin.  However, direct measurement of unbound drug in research and clinical 
practice is suggested for selected beta-lactams. 
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4.2.2 Introduction 
Infections are common in intensive care units (ICU), with over 50% of patients 
considered infected at any one time.3  Morbidity and mortality remains high among critically 
ill patients with infection and antibiotics are the single most effective intervention for 
reducing mortality rates.7, 8, 10-13  Complicating the likelihood of achieving effective antibiotic 
therapy are the effects of the complex disease processes that critically ill patients undergo and 
the associated significant effects on antibiotic pharmacokinetics (PK).  For the commonly 
used family of antibiotics, the beta-lactams, these PK changes, including those relating to 
altered protein binding, have been shown in numerous studies to result in high proportions of 
critically ill patients manifesting sub-therapeutic or toxic concentrations when standard dosing 
approaches are used.10, 54, 57, 86, 125, 261  Given the association between therapeutic antibiotic 
exposure and improved patient outcomes,35, 238 the use of therapeutic drug monitoring (TDM) 
to optimize beta-lactam exposures has been proposed as potentially useful for dose 
optimization in critically ill patients.125, 235, 237, 240, 262 
 
The existing reports for beta-lactam TDM have all used total antibiotic concentrations for 
determining the need for dose adjustment which is problematic given the unbound concentration 
of antibiotic is responsible for bacterial killing. The accuracy of such an approach is unclear. 
Given that hypoalbuminaemia occurs in approximately 40% of critically ill patients,66, 68 the 
potentially negative effects on altering protein binding of beta-lactam antibiotics may be 
common.47, 53, 67, 69  It is likely that direct measurement of unbound antibiotic concentrations 
should be preferred to calculating unbound concentrations from published protein binding values 
because such calculations may not reflect the unbound beta-lactam plasma concentration in a 
critically ill patient and therefore reducing the likelihood of achieving optimized therapeutic 
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dosing. Understanding the accuracy of protein binding of beta-lactams in this challenging patient 
population is essential to ensure optimal clinical dose adjustment. 
 
Given the uncertainty regarding protein binding changes in critically ill patients, the 
aim of this study was to compare the measured unbound concentration with the unbound 
concentration predicted from published protein binding values for seven beta-lactam 
antibiotics (ceftriaxone, cefazolin, meropenem, piperacillin, ampicillin, benzylpenicillin, and 
flucloxacillin).   
  
4.2.3 Materials and methods 
Patient selection 
 This observational study was conducted as part of a beta-lactam TDM program in 
critically ill patients at a 27-bed tertiary referral ICU.  Beta-lactam TDM is provided as a part 
of routine clinical care in this unit. Approval to collect this data was granted by the local 
institutional review board (Royal Brisbane and Women's Hospital, Human Research Ethics 
Committee). 
 
Ten antibiotics are included in the routine TDM service: ampicillin, benzylpenicillin, 
dicloxacillin, flucloxacillin, piperacillin, ceftriaxone, cephalothin, cephazolin, meropenem, 
and ertapenem.139, 140  Patients were eligible for inclusion in this analysis if they were >18 
years old, receiving one of the selected study antibiotic(s) and expected to remain on the 
treatment for the next 24 hours.  The empiric dosing regimen and subsequent dose adjustment 
was undertaken by the treating physician in consultation with the clinical pharmacist.  
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Various demographic and clinical data were collected to describe the patient sample including 
age, gender, weight, and plasma albumin and creatinine concentrations. Data for creatinine 
clearance on the sampling day was also collected, which was estimated from plasma 
creatinine concentrations using the Cockcroft-Gault equation.263 
 
Sampling 
 As per the TDM protocol, blood samples were obtained at assumed PK “steady state”, 
defined as sampling after administration of at least four prior doses.  For intermittent dosing, 
two plasma samples were obtained, firstly at the mid-point of the dosing interval and 
secondly, immediately prior to re-dosing (trough concentration).  For continuous infusion, 
plasma samples were taken after at least four half-lives.  Patients treated with more than one 
study antibiotic were eligible to provide more than one set of blood samples on the same day.   
 
Beta-lactam assays 
 Plasma total and unbound concentration of beta-lactams were determined using two 
different validated high-performance liquid chromatography (HPLC) assays, which have been 
published previously.139, 140  Briefly, to measure total beta-lactam concentrations, plasma 
samples were extracted with a known amount of internal standard and de-proteinated with 
acetonitrile.   The supernatant was added to chloroform, and the aqueous phase was analyzed 
using HPLC.  The concentration ranges of the standard curves were 1 – 500 mg/litre for all 
antibiotics (except for meropenem [1 – 250 mg/litre]). The coefficients of variation for inter-
assay and intra-assay precision were <10%, and the accuracy was within 6% for all 
antibiotics.  To measure unbound drug concentration, plasma sample were filtered by an 
Amicon Ultra-0.5 mL 30,000 molecular weight cut-off centrifugal filter device.  The 
ultrafiltrate were mixed with MES buffer (pH 6.6) and analyzed using HPLC.  The 
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concentration ranges of the standard curves were 0.1 - 50 mg/litre for all antibiotics (except 
for piperacillin [0.1 – 100 mg/litre]). The coefficients of variation for inter-assay and intra-
assay precision were <10%, and the accuracy was within 10% for all antibiotics.   
 
Calculation of unbound concentrations from total concentrations 
 Unbound concentrations of antibiotics were calculated from total concentrations using 
published percentage binding data as shown in Table 4.1.   
Table 4.1. Published percentages of protein binding for the study antibiotics. 
Antibiotic Reported avg protein binging (%) (range)ref 
Piperacillin 30%31 
Meropenem 2%264 
Ceftriaxone 89.5% (83 - 96%)45 
Ampicillin 20% (15 - 25%)265 
Cefazolin 80% (74 - 86%)266 
Benzylpenicillin 65%21 
Flucloxacillin 93%25 
 
In view of the saturable concentration-dependent protein binding kinetics of ceftriaxone, 
unbound concentrations of ceftriaxone were calculated from total concentrations (Ctot) using 
the following equation:56  
C free=
1
2
[−(nP+
1
k aff
−C tot)+√(nP+ 1k aff −C tot )
2
+
4Ctot
kaff
]
 
where capacity constant (nP) = 517 mol/litre and the binding affinity constant (Kaff) is 0.0367 
litres/mol. 
 
Statistics 
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 All continuous data were reported as means and standard deviations, or medians and 
interquartile ranges as appropriate.  Continuous data were analyzed using the Student t-test.  
Correlation between total and unbound antibiotic concentrations and covariations between 
continuous demographic and clinical variables with antibiotic concentrations and percentages 
of protein binding were determined using linear regression.  Bland-Altman plots were 
constructed with GraphPad (version 6.0a, Graphpad Software Inc) to assess the agreement 
between calculated unbound beta-lactams concentrations and measured unbound 
concentrations.  Percentage transformation was performed to increase the normality of the 
data for the constructions of Bland-Altman plots, as evaluated by Spearman’s rank correlation 
coefficient (ρ).  Bias, 95% limits of agreement and corresponding 95% confidence intervals 
were calculated as previously described.267  P values of < 0.05 were considered significant. 
 
4.2.4 Results 
One hundred and sixty-one patients were eligible for analysis, and their demographic 
and clinical characteristics are shown in Table 4.2.  Patients were typically male and older 
than 50 years old, with a serum albumin concentration below the normal range on the day of 
sampling.  Renal function, as described by plasma creatinine concentrations, was highly 
variable.  Forty-two patients had TDM performed on more than one occasion and one patient 
received two beta-lactams simultaneously.  Two hundred and twenty eight and 220 mid-
dosing and trough samples were assayed, respectively.  Due to limited sensitivity of the assay 
for total concentrations below 1 mg/L, 3 mid-dosing interval concentrations and 23 trough 
concentrations reported as <1 mg/L were excluded from the analysis.  The total number of 
samples included in the below analyses was 422.  Seventeen patients received continuous 
renal replacement therapy (CRRT) on the day of sampling.  
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Table 4.2. Demographics and clinical characteristics of the studied patients.  Data are 
described as mean + SD, or median (IQR) 
Characteristic  
Sex (% male) 59.6% 
Age (years) 52 ± 17 
Plasma creatinine concentration (μmol/L) 69 (30 – 381)  
Creatinine clearance (mL/min)** 131.9 ± 75.4 
Plasma albumin concentration (g/L) 24 ± 6 
Body weight (kg) 80.6 ± 22.4 
BMI (kg/m2) 27.6 ± 7.4 
* Plasma creatinine and plasma albumin concentrations were measured on the day of sampling; other parameters 
were measured upon admission. 
** Creatinine clearance was estimated using the Cockcroft-Gault formula 
 
Table 4.3.  Dosage ranges for studied beta-lactams. 
Antibiotic Dosage range 
Meropenem 500 mg 12-hourly – 2000 mg 6-hourly 
Piperacillin/ tazobactam 4500mg 12-hourly – 4500mg 6-hourly 
Ampicillin 1000 mg 8-hourly – 1000 mg 6-hourly 
Ceftriaxone 1000 mg 12-hourly – 2000 mg 8-hourly 
Cefazolin 1000 mg 8-hourly – 2000 mg 8-hourly 
Benzylpenicillin 1200 mg 4-hourly – 2400 mg 4-hourly 
Flucloxacillin 1000 mg 4-hourly – 2000 mg 4-hourly 
 
The dosage ranges for the prescribed antibiotics are shown in Table 4.3.  Variabilities 
in dosing regimens and resultant concentrations are observed, with marked deviations of 
predicted concentrations from the line of identity in particular for piperacillin and 
benzylpenicillin at both sampling times, and for trough concentrations of meropenem, 
ceftriaxone (Fig 4.1a) and flucloxacillin.  Measured unbound concentrations tended to be 
higher than predicted for ceftriaxone at all concentrations, and for piperacillin, 
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benzylpenicillin and flucloxacillin especially at higher concentrations.  However, measured 
unbound concentrations were only significantly higher (p<0.05) than predicted for 
ceftriaxone at both sampling times and for flucloxacillin at mid-dosing interval.  The 
percentage of unbound piperacillin was significantly higher at the trough time point in 
patients receiving CRRT (82.5%, versus 69.6% in non-CRRT patients; p<0.01).  No 
significant relationship was observed for other studied beta-lactams. 
 
Figure 4.1.  Linear correlation between measured and predicted unbound trough 
concentrations of a) ceftriaxone and b) cefazolin (R2 = 0.96, p=0.003).  The x=y plots is 
shown as the grey dashed line. 
 
 A linear correlation between the measured and predicted unbound concentrations was 
established for all studied beta-lactams except ceftriaxone and flucloxacillin.  Linear 
regression correlations between total and unbound concentrations described using an R2 value 
were between 0.81 and 1.00 for beta-lactams (p≤0.001 for all except cefazolin (Fig 4.1b), 
p=0.003).  A non-linear correlation between the measured and predicted unbound 
concentrations was observed for flucloxacillin (R2=0.91) 
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 The predictive performance of the calculated unbound beta-lactams trough 
concentrations was assessed by Bland-Altman plots, as shown in Figure 4.2 and Table 4.4.  
Biases in calculated unbound concentrations were observed for ceftriaxone, flucloxacillin and 
benzylpenicillin, where actual (measured) unbound concentrations were underpredicted.  For 
meropenem and cefazolin, the calculated unbound concentrations biased for overpredicting 
unbound concentrations.  The 95% limits of agreement for calculated unbound concentrations 
as a predictor of measured unbound concentrations were wide for the majority of studied beta-
lactams. 
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Figure 4.2.  Bland-Altman plots of relative difference (percentage of measured unbound 
concentrations) against mean of predicted and measured unbound concentrations for a) 
piperacillin (n=94, ρ= -0.51, p<0.01); b) ampicillin (n=8, ρ=0.42, p=0.30); c) benzylpenicillin 
(n=11, ρ= -0.92, p<0.01); d) meropenem (n=49, ρ=0.02, p=0.91); e) ceftriaxone (n=19, ρ= -
0.43, p=0.07); f) cefazolin (n=5, ρ= -0.80, p<0.01), and g) flucloxacillin (n=11, ρ= -0.81, 
p<0.01).  The bias and 95% limits of agreement were shown in solid (          ) and broken (-----
-) horizontal lines respectively. 
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Table 4.4.  Performance evaluation of calculated unbound concentrations as a predictor of 
measured unbound concentrations using bias, 95% limits of agreement and associated 
confidence intervals (CIs) as determined by Bland-Altman plots. 
 Bias 95% CI (bias) 
95% limits of 
agreement 
95% CI  
(lower limit) 
95% CI  
(upper limit) 
Piperacillin 0.43% -6.6% to 7.4% (-34.7%, 39.6%) -41.7% to -27.7% 33.6% to 46.6% 
Ampicillin -5.08% -15.5% to 5.4% (-22.2%, 12.0%) -32.7% to -11.7% 1.5% to 22.5% 
Benzylpenicillin -25.00% -57.4% to 7.4% (-86.97%, 37.0%) -119.3% to -54.6% 4.6% to 69.4% 
Meropenem 12.08% 6.6% to 17.6% (-10.2%, 34.4%) -15.7% to -4.7% 28.8% to 39.9% 
Ceftriaxone -83.30% -117.2% to -49.4% (-168.5%, 1.9%) -202.4% to -134.6% -32.0% to 35.8% 
Cefazolin 9.33% -41.1% to 59.7% (-55.7%, 74.4%) -106.1% to -5.3% 24.0% to 124.8% 
Flucloxacillin -56.80% -130.1% to 16.5% (-197.2%, 83.6%) -270.5% to -123.9% 10.3% to 156.9% 
  
 No significant associations were found between percentage of binding and albumin 
concentrations for any of the beta-lactams studied except flucloxacillin (R2 =0.76; p<0.01).  
For cefazolin, the relationship between percentage of protein binding and albumin 
concentrations was not analyzed due to inadequate albumin concentration data available for 
those subjects.    
 
4.2.5 Discussion 
 In this study of critically ill patients, we compared the observed unbound 
concentration of beta-lactam antibiotics with the unbound concentration predicted using 
published protein binding values. This data confirms the high variability and in some cases 
unpredictability of unbound beta-lactam concentrations in critically ill patients.  The present 
work is unique in terms of the number of antibiotics studied and the evaluation of predictive 
performance for calculating unbound beta-lactams concentrations using published protein 
binding values in critically ill patients.   
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 The efficacy of beta-lactams has been well defined according to the time that the 
unbound (or free) concentration exceeds the minimum inhibitory concentration (MIC; f T>MIC) 
of the bacterial pathogen.  Traditionally, most assays used in PK studies in critically ill 
patients measure total beta-lactam antibiotic concentrations and subsequently, calculate 
unbound concentrations from published plasma protein binding data that has been obtained 
from non-critically ill patient groups.   
 
Since variation in protein binding and prevalence of hypoalbuminaemia among the 
critically ill has been observed in other studies,53, 70, 140 there is increasing concern of the 
accuracy of this estimation, especially for high protein bound drugs in the critically ill.  Since 
the time course of unbound beta-lactam concentrations is more relevant than total 
concentration, direct measurement of the unbound fraction has been suggested to have 
potential advantage in antibiotic dose optimization in the critically ill.  In this study, we 
utilized a rapid and inexpensive assay for measurement of unbound beta-lactam 
concentrations in clinical practice.  The data presented again demonstrate severely altered PK 
of beta-lactams in the critically ill patients.   
  
 As expected, in our cohort of critically ill patients with low plasma albumin 
concentrations (mean, 24.5 g/litre), significant differences between predicted (from total 
concentrations) and measured unbound concentrations were found for the highly protein 
bound antibiotics ceftriaxone and flucloxacillin.  The mean percentage of protein binding for 
ceftriaxone (87.3 to 87.7%) determined in this study lies within the lower limits (83 to 96%) 
found in healthy volunteers,268 yet is similar to that found in a group of surgical critically ill 
patients (85.5 - 91.5%).61  However, when we used a saturable model of ceftriaxone protein 
binding with published binding parameters to predict unbound concentrations from our total 
  73 
concentrations data, percentage of protein binding was approximated to be around 95%, 
suggesting over estimation of protein binding by the model when applied to our patient 
cohort.  Nevertheless, no significant correlation between albumin concentrations and the 
unbound fraction of ceftriaxone was found in this study.   On the other hand, correlation 
between albumin concentrations and the unbound fraction was found for flucloxacillin, as 
observed previously in a cohort of septic neonates and adult critically ill patients, with both 
groups having lower-than-normal plasma albumin concentrations.70, 269  Of note, significant 
differences between measured and calculated unbound flucloxacillin concentrations were 
found only at the higher concentrations at the mid-dosing time point but not at the trough time 
point.  This may reflect the nonlinearity of protein binding at high concentrations and, thus, 
poor prediction of unbound values in this range.  
 
 A reduction of unbound fraction for meropenem from 98% in healthy volunteers to a 
median of <90% was observed among our patients.  Despite this fact, there was no significant 
difference between measured and predicted unbound meropenem concentrations, possibly due 
to its relative low fraction of protein binding, where a small change in percentage of binding 
would alter the unbound drug concentrations only minimally.25, 71  Our data demonstrate that 
plasma protein binding of beta-lactams in critically ill patients is highly variable, and a 
correlation with albumin concentration exists only for selected agents.  Although linear 
correlations between total and unbound concentrations exist for some of the studied beta-
lactams, the predictive performance of calculated unbound concentrations was of concern in 
terms of underdosing especially for piperacillin at low concentrations (<50 mg/L) and for 
meropenem, where unbound concentrations were consistently overpredicted at a limited but 
considerable magnitude.  Another important finding from this analysis was that for 
ceftriaxone, benzylpenicillin and flucloxacillin, the observed unbound concentration was 
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higher than the predicted concentration meaning that dose adjustments based on the low 
predicted unbound concentrations may not always be required. Dose adjustments for possible 
concentration-related adverse events may also not be accurate in this context.  The unbound 
concentration assay used in this study is an inexpensive and convenient means to overcome 
the limitation of predicting unbound drug concentrations under these circumstances. 
 
Limitations of the study 
Firstly, the variability of clinical conditions and interventions that can vary beta-lactams PK 
in the critically ill, as well as the small cohort of patients and samples available for the 
analysis of some antibiotics (namely cefazolin, benzylpenicillin, and flucloxacillin) could be 
considered a limitation of this study.  Nevertheless, this is the largest data set of unbound 
measurements of these drugs.  Secondly, the assay used in this study has limited sensitivity 
for total beta-lactam concentrations of < 1 mg/litre, such that conversion from total to 
unbound concentrations was not established for this low concentration range.  Finally, the 
95% limits of agreement as determined by Bland-Altman plots depend on the assumption that 
the differences between the two measurement methods are constant throughout the range of 
measurements and follow a Gaussian distribution.  Although percentage transformation (or 
logarithmic transformation [data not shown]) improved the distribution of our data, the 
percentage differences between predicted and measured unbound concentrations still 
significantly varied with the means of the two measurements for benzylpenicillin, 
flucloxacillin, piperacillin, and cefazolin.  However, the analysis used provides sufficient 
information on bias and precision of calculating unbound concentrations from total measured 
concentrations to conclude whether the predictive performance of the calculated unbound 
concentrations is adequate in the clinical context. 
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In summary, this is the first paper that directly compares measured total and unbound 
beta-lactam antibiotic concentrations in critically ill patients.  We found a high variability in 
beta-lactam concentrations and plasma protein binding in a cohort of critically ill patients.  A 
correlation between percent protein binding and plasma albumin concentrations was observed 
only in flucloxacillin.  Given the variability of unbound beta-lactam concentrations in 
critically ill patients and the clinical importance of unbound drug concentrations, utilization of 
an inexpensive and convenient assay for determination of unbound drug concentrations in 
research and clinical practice is suggested.   
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4.3 Conclusion 
In this chapter we described the effect of hypoalbuminaemia on unbound beta-lactams 
concentrations in critically ill patients, given the prevalence of hypoalbuminaemia in this 
population.  The correlation between percent protein binding and plasma albumin 
concentrations was poor.  We evaluated the predictive performance of the traditional method 
to calculate unbound beta-lactam concentrations using published protein binding data, and 
demonstrated the risk of under-estimation for highly protein-bound beta-lactams; whereas 
unbound piperacillin (at low concentrations) and meropenem were consistently over-
predicted.  These data support the direct measurement of unbound beta-lactams for TDM in  
clinical setting.
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Chapter 5  The effect of measurement of unbound beta-lactam concentrations during  
therapeutic drug monitoring on the need for dose adjustment in critically 
ill patients 
 
5.1  Synopsis 
The aim of this chapter is to describe the achievement of unbound beta-lactam antibiotic 
concentration targets in a TDM programme in critically ill patients, and the factors associated 
with failure to achieve a target concentration.  The relationship of achieving pre-defined  
PK/PD targets and clinical outcome is also explored.
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5.2 Published article entitled, “Therapeutic drug monitoring of beta-lactam 
antibiotics in the critically ill: direct measurement of unbound drug concentrations to 
achieve appropriate drug exposures” 
 
The manuscript entitled, “Therapeutic drug monitoring of beta-lactam antibiotics in the 
critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug 
exposures” has been accepted for publication by The Journal of Antimicrobial Chemotherapy 
(2018; 73(11): 3087-3094). 
 
The co-authors contributed to the manuscript as follows: Study design and data collection was 
performed by the PhD candidate, Gloria Wong, under the supervision of Prof. Jason A. 
Roberts. Analysis of data was performed by the PhD candidate, Gloria Wong, under the 
guidance of Prof. Jason A. Roberts and Prof Jeffrey Lipman. The PhD candidate, Gloria 
Wong, took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published, except figures and tables have been inserted into 
the text at slightly different positions. Also, the numbering of pages, figures and tables has 
been adjusted to fit the overall style of the Thesis. The references are found alongside to the 
other references of the Thesis, in the section ‘Reference’. 
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5.2.1 Abstract 
Objectives: To describe the achievement of unbound beta-lactam antibiotic concentration 
targets in a TDM program in critically ill patients, and the factors associated with failure to 
achieve a target concentration.  
Patients and methods: Plasma samples and clinical data were obtained for analysis from a 
single center prospectively.  Unbound concentrations of ceftriaxone, cefazolin, meropenem, 
ampicillin, benzylpenicillin, flucloxacillin and piperacillin were directly measured using 
ultracentrifugation.  Factors associated with achievement of PK/PD targets or negative 
clinical outcomes were evaluated with binomial logistic regression. 
Results: TDM data from 330 patients, and 369 infection episodes, were included.  The range 
of doses administered was 99.4% ± 45.1% relative to a standard daily dose.  Dose increases 
were indicated in 33.1% and 63.4% of cases to achieve PK/PD targets of 100% fT>MIC and 
100% fT>4xMIC, respectively.  Dose reduction was indicated in 17.3% of cases for an upper 
PK/PD threshold of 100% fT>10xMIC. Higher protein bound beta-lactams (ceftriaxone and 
benzylpenicillin) had better therapeutic target attainment (p<0.01), but were prone to 
excessive dosing. Augmented renal clearance (CLCR>130 mL/min) increased the odds in 
failure to achieve 100% fT>MIC and 100% fT>4xMIC (OR 2.47 and 3.05 respectively; p<0.01).  
Conclusions: Measuring unbound concentrations of beta-lactams as part of a routine TDM 
program is feasible and demonstrates that a large number of critically ill patients do not 
achieve predefined PK/PD targets.  Clinical significance of this finding is unknown due to the 
lack of correlation between PK/PD findings and clinical outcomes. 
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5.2.2 Introduction 
 Mortality and morbidity associated with severe infections remain high among the 
critically ill despite advances in modern medicine.3, 270  Early and targeted antibiotic treatment 
is the cornerstone of managing infections in critically ill patients, especially those with 
sepsis.14   However, achieving adequate antibiotic exposure in the critically ill through using 
conventional dosing regimens is challenging.  Significantly altered beta-lactam antibiotic PK 
in the critically ill can result from patients’ dynamic and deranged pathophysiology such as 
altered fluid balance and augmented renal clearance (ARC).62, 99, 271  On the other hand, 
patients with organ dysfunction and associated impaired drug clearance are prone to 
inappropriately high drug exposures and possible drug toxicities.131, 133, 235  Thus, standard 
antibiotic dosing regimens derived from healthy volunteers and non-critically ill patient may 
not be appropriate.  Strategies that aim to optimize antibiotic exposure using PK/PD data have 
been proposed to improve clinical outcomes in infected critically ill patients.125, 130, 132, 235 
 Beta-lactams are the most frequently used antibiotics for treatment of severe 
infections in the critically ill.  Efficacy of beta-lactams depends on the percentage of the 
dosing period that the unbound concentration of the antibiotic is maintained above the MIC of 
targeted pathogen (% fT>MIC).  Early in vitro and animal in vivo studies demonstrated that 40-
70% fT>MIC is associated with bactericidal effect,
37, 272 while clinical data suggests a higher 
threshold of up to 100% fT>4xMIC is associated with positive clinical outcomes.
108  In view of 
the extremely deranged and unpredictable beta-lactam PK in the critically ill, TDM has been 
proposed as a strategy to optimize % fT>MIC and to potentially improve clinical outcomes.  
However, currently available TDM reports have not directly accounted for altered protein 
binding, and the associated change in unbound beta-lactams concentrations,141 despite the 
high prevalence of hypoalbuminaemia causing altered protein binding in the critically ill.66 
Given that efficacy is dependent on the unbound rather than total plasma concentration of 
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antibiotic, knowledge of unbound concentrations when applying TDM should be considered 
essential. 
The primary aim of this study was to describe the achievement of unbound beta-
lactam antibiotic concentration targets in a TDM program in critically ill patients. 
Furthermore, we sought to describe the factors associated with target achievement. The 
secondary aims were to identify factors associated with failure to achieving PK/PD targets 
and negative clinical outcomes. 
 
5.2.3 Materials and methods 
Patient selection 
 This prospective observational study was conducted as part of a beta-lactam TDM 
program in critically ill patients at a 27-bed tertiary referral ICU.  Beta-lactam TDM is 
provided as a part of routine clinical care in this unit. Approval to collect this data was 
granted by the local institutional review board (Royal Brisbane and Women's Hospital, 
Human Research Ethics Committee).  Data were collected over the period between 1 January 
2012 and 19 December 2013. 
 
Ten antibiotics are included in the routine TDM service: ampicillin, benzylpenicillin, 
dicloxacillin, flucloxacillin, piperacillin (co-administered with tazobactam), ceftriaxone, 
cefalothin, cefazolin, meropenem and ertapenem. Patients were eligible for inclusion in this 
analysis if they were >18 years old, receiving one of the selected study antibiotic(s), would 
have received at least four doses of antibiotic by the time of sampling and were expected to 
remain on the treatment for the next 24 hours.  
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Demographic and clinical data were collected to describe the patient sample including age, 
sex, weight, serum albumin and creatinine concentrations, indications for antibiotic treatment, 
antibiotic dosing data (including dose, administration frequency, duration of infusion, dosing 
time and duration of antibiotic therapy), admission diagnosis and clinical outcome of infection 
treatment.  Microbiological data collected include identity of cultured bacteria and its 
corresponding MIC, if available.  Creatinine clearance (CLCR) on the sampling day was 
estimated from serum creatinine concentrations using the Cockcroft-Gault equation.263 
 
Initial dose selection and dose adjustment strategy 
The treating physician in consultation with the clinical pharmacist determined the 
empiric dosing regimen and performed subsequent dose adjustment.  Empiric doses were 
prescribed based on the patients’ clinical condition (including hemodynamic status, renal and 
hepatic functions) and known or likely pathogen.  Loading doses were given when continuous 
infusion was used.  Subsequent dose adjustment was made according to approach described in 
Table 5.1. 
Table 5.1. Dose adjustment strategy  
Unbound 
concentration 
Dose adjustment 
<100% f T>MIC 25-50% increased frequency of same dose; change of 
administration to extended infusion (infused over one-half of 
the dosing interval) if TDM concentration within 20% of target 
concentration; or change to continuous infusion (same day 
dose) when intermittent dosing at maximum dose in line with 
the antibiotic's product information 
>100% f T>10xMIC 50% decreased dose with same dosing frequency; or 25-50% 
decreased frequency with same dose 
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Sampling 
 As per the TDM protocol, blood samples were obtained at assumed PK ‘steady state’, 
defined as sampling after administration of at least four prior doses.  For intermittent dosing, 
two plasma samples were taken, firstly at the mid-point of the dosing interval and secondly, 
immediately prior to re-dosing (trough concentration), respectively.  For continuous infusion, 
plasma samples were taken after at least four half-lives.  Patients treated with more than one 
study antibiotic were eligible to provide more than one set of blood samples on the same day.   
 
Beta-lactam assay 
 Plasma unbound concentration of beta-lactams were measured directly using a 
validated and previously published HPLC assay.140  Briefly, plasma samples were filtered by 
an Amicon Ultra-0.5 mL 30,000 molecular weight cut-off centrifugal filter device.  The 
ultrafiltrate were mixed with MES buffer (pH 6.6) and analyzed using HPLC.  The 
concentration ranges of the standard curves were 0.1 - 50 mg/L for all antibiotics (except 
piperacillin 0.1 – 100 mg/L). The coefficients of variation for inter-assay and intra-assay 
precision were <10%, and the accuracy was within 10% for all antibiotics.  
  
Beta-lactam TDM service 
 The TDM-service was provided twice weekly by the in-house pathology laboratory.  
Typically results were available within 12 hours (maximally within 24 hours) when samples 
were taken on the morning of scheduled service day. 
 
PK/PD targets for dose adjustment 
The PK/PD target of 100% fT>MIC was chosen for dose adjustment in this study.  The 
upper limit of 100% fT>10xMIC was arbitrarily selected for dose reduction as indicative of an 
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exposure beyond which no therapeutic value is likely, but for which there may be an 
increased possibility of toxicity.  The EUCAST’s clinical breakpoint specific for the targeted 
(or suspected) bacteria was used (http://www.eucast.org/clinical_breakpoints) when a 
measured MIC was not available.  The highest MIC for a suspected susceptible bacteria to the 
antibiotic was used in cases where no pathogen was cultured (e.g. 16mg/L for anti-
Pseudomonas activity for Piperacillin/tazobactam). 
 
Clinical endpoints definitions 
 Clinical outcomes are defined in Table 5.2.  Data were extracted from patients’ 
medical notes where clinical progress was documented by independent treating physicians. 
Table 5.2. Definitions of clinical outcomes 
Clinical response Definition 
Positive clinical 
outcome 
Resolution (disappearance of all signs and symptoms 
related to the infection) or improvement (marked or 
moderate reduction in the severity and/or number of signs 
and symptoms of infection) clinically as documented by 
independent clinicians in patients’ progress notes.   
Negative clinical 
outcome 
Any outcome other than positive outcomes, which 
includes insufficient lessening of the signs and symptoms 
of infection to qualify as improvement, including death or 
indeterminate (no evaluation possible, for any reason).   
 
Safety analysis 
 Data were extracted from patients’ medical notes where probable adverse drug 
reactions related to studies beta-lactams were documented by independent treating physicians. 
  
Statistics 
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 All continuous data are reported as number (percentages), or medians (IQR) as 
appropriate.  Achievement of various PK/PD targets (50% fT>MIC (most conservative), 50% 
fT>4xMIC, 100% fT>MIC, and 100% fT>4xMIC) are reported as percentages. For patients with two 
or more TDM occasions during a single course of antibiotic therapy, achievement of PK/PD 
targets among first and subsequent TDM were compared using McNemar’s test.  The 
association of patient demographic and clinical factors with achievement of PK/PD targets 
was evaluated with binomial logistic regression using SPSS (version 22.0, Illinois, USA) for 
all patients.  Factors associated with negative clinical outcome were analyzed for cases where 
respiratory, abdominal or blood stream infections were being treated, and analyzed relative to 
the outcome associated with blood stream infections.  Cases where there was more than one 
identified source of infection were not included in the analysis.  ORs and 95% CIs were 
obtained.  P values < 0.05 were considered significant. 
 
5.2.4 Results 
Three hundred and seventy three (373) patients were included in the study and the 
demographic and clinical characteristics of 330 evaluable patients (369 cases of infection) are 
shown in Table 5.3. 
Table 5.3. Demographics and clinical characteristics of the studied patients.  Data are 
described as N (%), mean + SD, or median [IQR] 
Characteristic  
Sex (% male) 66% 
Age (years) 53.4 ± 17.7 
Serum albumin concentration (g/L)* 24.2 ± 5.6 
Serum creatinine concentration (μmol/L)* 76 [53-129] 
Calculated creatinine clearance (mL/min)** 101.5 [59.1-163.0] 
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RRT 68 (13.8%) 
BMI (kg/m2) 29.0 ± 8.9 
APACHE II score 22 [16-27] 
Repeated sampling (2nd or subsequent) 122 (24.8%) 
Duration of beta-lactam therapy (days) 5 [3–7] 
Antibiotic administered as continuous infusion 21 (4.3%) 
Percentage of standard daily dose 99.4% ± 45.1% 
* Serum creatinine and serum albumin concentrations were measured on the day of sampling; other parameters 
were measured upon admission. 
** Creatinine clearance was estimated using the Cockcroft-Gault formula 
 
Patients were typically male and with a high mean BMI, 29.0 kg/m2.  Serum albumin 
concentrations were consistently below the normal range on the day of sampling and renal 
function was highly variable, as described by serum creatinine concentrations.  Sixty-eight 
patients (13.8%) were receiving CRRT on the day of sampling. In 192 cases (39.1%), patients 
manifested ARC (calculated CLCR >130 mL/min).  One hundred and three patients (31.2%) 
had TDM performed on more than one occasion.  Four hundred thirty-eight (438) and 491 
mid-dosing and trough samples were measured, respectively.  MIC data was available for 12 
culture positive samples.  Treatment was initiated for respiratory infection in the majority of 
cases (35.0%), followed by blood stream and intra-abdominal infections (16.8% and 9.2% 
respectively).  In 10.3% of cases, more than one source of infection was identified.  The 
dosing ranges for the prescribed antibiotics are shown in Figure 5.1.  The range of doses 
administered was wide with an observed variation relative to a standard daily dose of 99.4% ± 
45.1%.  Among patients manifested ARC, doses administered were above standard daily dose 
(range 133.3% to 400% of standard daily dose) in fifty-three cases (27.6%).  None of the 
study participants received dicloxacillin, cefalothin or ertapenem during the data collection 
period.   
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Figure 5.1. Range of beta-lactam doses administered relative to standard daily dose 
(meropenem, 1000mg 8-hourly; piperacillin/tazobactam, 4500mg 8-hourly; ampicillin, 
2000mg 6-hourly; ceftriaxone, 1000mg 12-hourly; cefazolin, 1000mg 8-hourly; 
benzylpenicillin, 2400mg 4-hourly; and flucloxacillin, 2000mg 4-hourly) 
 
 The overall achievement of predefined PK/PD targets for dose increases are shown in 
Table 5.4 and Figure 5.2.  The majority of cases (90.1%) achieved the conservative target of 
50% fT>MIC, with the exception of ampicillin where attainment of this target was significantly 
lower (60.0%).  Success in target achievement decreased considerably as the magnitude of the 
PK/PD target increased, with only 36.6% cases achieving the target of 100% fT>4xMIC.  For 
cefazolin, no patients achieved this target.  Among the tested beta-lactams, benzylpenicillin 
and ceftriaxone achieved the upper target of 100% fT>4xMIC in 80.0% and 71.4% of the cases 
respectively.  On the other hand, there was high proportion of cases (80.0% and 49.3% among 
patients received benzylpenicillin and ceftriaxone, respectively) where dose reduction was 
required because of a high PK/PD index (100% fT>10xMIC).  
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Figure 5.2.  Pharmacokinetic/pharmacodynamic ratios (as unbound concentrations divided by 
MICs) at 50% and 100% dosing interval.  Dotted lines denote predefined targets of fT>MIC and 
fT>4xMIC at respective dosing intervals. 
 
 
 
  90 
Table 5.4. Achievement of predefined pharmacokinetic/pharmacodynamic (PK/PD) dose adjustment targets for first TDM of studied beta-
lactams.   
 
 % of episodes where predefined targets were reached (within each beta lactam group)  
Beta-lactam Ampicillin Benzylpenicillin Cefazolin Ceftriaxone Flucloxacillin Meropenem Piperacillin Total 
Standard dose 2000 mg 6-hourly 2400 mg 4-hourly 1000 mg 8-
hourly 
1000 mg 12-
hourly 
2000mg 4-hourly 1000 mg 8-hourly 4500 mg 8-hourly  
Dosage range 1000 mg 12-
hourly – 2000 mg 
4-hourly 
1200 mg 4-hourly – 
2400 mg 4-hourly 
1000 mg 6-
hourly – 2000 
mg 8-hourly 
1000 mg 12-
hourly – 2000 mg 
8-hourly 
2000 mg 12-
hourly – 2000 mg 
2-hourly 
500 mg 12-hourly 
– 2000 mg 6-
hourly 
4500mg 12-hourly 
– 4500mg 4-
hourly 
 
50% fT >MIC 60.0%* 100.0% 100.0% 96.2% 83.3% 92.1% 90.4% 90.1% 
50% fT >4xMIC 53.3% 91.7%* 28.6% 96.2%* 44.4% 68.5% 53.2% 61.3% 
Total (n) 15 15 7 26 18 89 156 323 
100% fT >MIC 53.3% 93.3%* 57.1% 96.4%* 52.0% 72.2% 61.0% 66.9% 
100% fT >4xMIC 33.3% 80.0%* 0.0% 71.4%* 32.0% 29.9% 33.5% 36.6% 
100% fT >10xMIC 13.3% 80.0%* 0.0% 39.3% 16.0% 11.3% 13.2% 17.3% 
Total (n) 15 15 7 28 25 97 182 369 
* percentage of episodes achieving corresponding PK/PD targets significantly different from other beta-lactam antibiotics (p<0.05) 
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Paired comparison of PK/PD targets achievement between first and subsequent TDM 
measurements were performed for patients with two or more TDM measurements (n=84 at 
mid-dosing interval, n=94 at trough).  No significant difference was found in PK/PD ratios 
achieved and percentage of cases achieving the predefined PK/PD targets in first TDM as 
compared to subsequent TDM indicating that the dose adjustment schedule was not efficient 
(Table 5.5). 
 
Table 5.5.  Achievement of pharmacokinetic/pharmacodynamic (PK/PD) dose adjustment 
targets for first versus subsequent TDM for patients that had sampling on more than one 
occasion (n=84 at mid-dosing interval, n=94 at trough).  PK/PD ratios and percentage of cases 
achieving the predefined PK/PD targets in first TDM as compared to subsequent TDM were 
not significantly different. 
 First TDM Subsequent TDM 
PK/PD ratio  
(at mid-dosing interval) 
4.0 [2.3 – 8.5] 4.3 [2.3 – 8.5] 
PK/PD ratio (at trough) 1.8 [0.6 – 4.7] 1.6 [0.7 – 3.4] 
Achievement of PK/PD targets 
50% fT>MIC   
Yes 76 (90.5%) 76 (90.5%) 
No 8 (9.5%) 8 (9.5%) 
100% fT>MIC   
Yes 59 (62.8%) 61 (64.9%) 
No 35 (37.2%) 33 (35.1%) 
50% fT>4xMIC   
Yes 42 (49.4%) 45 (52.9%) 
No 43 (50.6%) 40 (47.1%) 
100% fT>4xMIC   
Yes 25 (26.6%) 21 (22.3%) 
No 69 (73.4%) 73 (77.7%) 
>100% fT>10xMIC   
Yes 11 (11.7%) 8 (8.5%) 
No 83 (88.3%) 86 (91.5%) 
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 Factors that predicted a failure to achieve the various unbound PK/PD targets (for first 
TDM) were explored.  Augmented renal clearance (calculated CLCR >130 mL/min) was 
significantly associated with not achieving all predefined PK/PD targets (OR 2.47-3.33, 
p<0.05).  Administration by prolonged infusion (continuous or extended infusion) was 
associated with a decreased the likelihood of achieving 100% fT>MIC (OR 0.28, [95% CI 0.09-
0.86]; p=0.026).  The type of beta-lactam used was also significantly associated with the 
successful achievement of all PK/PD targets except 50% fT>MIC (p<0.01). 
   
Overall, dose reduction was indicated in 17.3% of cases.  Excessive drug exposure 
was associated with impaired renal clearance for a calculated CLCR <50 mL/min (OR 9.12, 
[95% CI 3.05-27.25]; p<0.01) and calculated CLCR 51-90 mL/min (OR 3.21, [95% CI 1.10-
9.41]; p=0.03). 
 
Two hundred and seventy five cases (71.2%) had a positive clinical outcome.  There 
were 41 deaths among the studied patients. The percentage of positive clinical outcome in 
cases where respiratory, abdominal or blood stream infections were being treated (73.6%, 
n=220) was comparable to the overall studied population (71.2%).  An abdominal source of 
infection significantly increased the odds of negative clinical outcome (OR 7.60, [95% CI 
2.39-24.17]; p=0.001).  Overall, failure to achieve PK/PD targets was not found to be 
independently associated with negative clinical outcomes in this patient sample with positive 
microbiological cultures (OR 0.88, [95% CI 0.40-1.91]; p=0.74, OR 0.67, [95% CI 0.29-
1.55]; p=0.35, for 100% fT>MIC and 100% fT>4xMIC respectively).   
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Adverse effects deemed causally related to beta-lactam antibiotic therapy was reported 
in 5 cases.  Neurotoxicity and nephrotoxicity were reported in one patient where trough free 
benzylpenicillin concentration reached 31 mg/L (beyond 10 times of the targeted MIC).  Mild 
hepatotoxicity was reported in the other 4 cases, where none of them reached the predefined 
target for dose reduction. 
 
5.2.5 Discussion 
 This study has uniquely evaluated achievement of PK/PD targets of directly measured 
unbound antibiotic concentrations for a large number of beta-lactam antibiotics which, to the 
best of our knowledge, has not been previously reported. Hypoalbuminaemia in the critically 
ill is common, and previous study demonstrated poor predictive performance of calculated 
unbound drug concentration using conventional method.141  Given the variability of unbound 
drug fraction in the setting of hypoalbuminaemia, calculation of the unbound beta-lactam 
antibiotics concentration using published protein binding data tends to underestimate the true 
unbound concentration of highly protein bound beta-lactams, while overestimate unbound 
concentrations of some important beta-lactams such as meropenem and 
piperacillin/tazobactam. Using a simple HPLC-UV-based method in clinical setting, we aim 
to better characterize the beta-lactam antibiotic exposures in the critically ill.  We found that 
for the majority of tested beta-lactams, attainment of PK/PD targets was sub-optimal, with the 
exception of relatively highly protein bound benzylpenicillin and ceftriaxone. Even with the 
pre-defined empiric dose adjustment strategy, target attainment at subsequent TDM 
measurements was not high, although appeared to reduce the odds of excessive dosing.   
  
Our study echoes the concerns raised in other beta-lactams PK/PD studies in the 
critically ill where significant numbers of patients did not achieve empiric PK/PD targets.81, 
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125  Despite the fact that a large proportion of our studied population received beta-lactams at 
a non-standard dose that was adjusted according to their clinical condition as shown in Table 
5.4, almost half of the cases did not achieve 100% fT>MIC.  Achievement of 50% fT>MIC was 
significantly lower for ampicillin compared with the other tested beta-lactams suggesting that 
empiric dosing for this drug requires urgent revision.  Interestingly, administration by 
prolonged infusion (continuous or extended infusion) was associated with a decreased the 
likelihood of achieving 100% fT>MIC. This finding is unexpected, given the theoretical 
advantage of continuous infusion over short infusion in attaining PK/PD targets for beta-
lactams, as previously demonstrated in critically ill patients with severe sepsis273 and in those 
subjected to CRRT.274, 275  However, using population pharmacokinetics model, Dhaese et al. 
demonstrated even a high dose continuous infusion regimen (4 g loading dose followed by 
continuous infusion of 24 g/24 hours) was inadequate to achieve a targeted exposure of 100% 
fT>4xMIC against susceptible Pseudomonas aeruginosa isolates (MIC 16 mg/L) in critically ill 
patients with normal or augmented renal clearance (>90 mL/min/1.73 m2).276  Similar analysis 
for unbound flucloxacillin also showed continuous infusion at a higher than standard dose (12 
g/24 hours) is needed to achieve a more aggressive PK/PD target.70  Our observations reflect 
the difficulty in determining dosing regimen in this group of patient, where high renal 
clearance was anticipated and continuous infusion was used preemptively.  Relatively highly 
protein bound beta-lactams such as ceftriaxone (83-95% protein bound) and benzylpenicillin 
(65%) had better PK/PD target attainment.  This may be explained by the higher unbound 
fraction of drug in the setting of hypoalbuminaemia in the critically ill, in combination with 
relatively lower MIC targets for these antibiotics (e.g. Streptococcus pneumoniae 0.125 mg/L 
for both antibiotics).  Interestingly, the same results were not observed for flucloxacillin, 
which is also highly protein bound (95%).  
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Although it is important to maintain adequate beta-lactams exposure when treating the 
critically ill, the risk of unnecessarily excessive drug exposure should not be overlooked.  In 
this study, dose reduction was indicated in 17.3% of cases (first TDM) when trough 
concentrations reached above 10 times of targeted MIC.  Although there is limited evidence 
that this target is an indicator of toxicity, it was chosen for dose reduction arbitrarily in this 
study, based on the likelihood of extra therapeutic value beyond that level is limited.  Patients 
administered the relatively highly protein bound benzylpenicillin (65%) or ceftriaxone (83-
95%) and/or patients with significantly impaired renal function (CLCR <50 mL/min) were 
most susceptible to over-exposure of antibiotics; but those with relatively nomal renal 
function (CLCR 51-90 mL/min) were also at risk.  Beta-lactams are considered to be generally 
safe at high doses and have a wide therapeutic window.  However, neurological adverse 
events associated with cephalosporins and carbapenems in particular has been widely reported 
in critically ill patients and those with renal impairment in general.131, 133, 277  Clinicians 
should be vigilant about the potential risk of excessive beta-lactam concentrations. Indeed, 
fluctuations of patient’s renal function should prompt closer monitoring of drug 
concentrations and associated hidden complications such as encephalopathy and non-
convulsive epilepsy.  Practically, assays that directly measure unbound beta-lactam should be 
used, especially for high protein bound antibiotics.  In the setting of hypoalbuminaemia in the 
critically ill, there is a risk of underestimating unbound antibiotic concentrations when 
correcting total measured concentrations with published protein-binding data.141 This can lead 
to inappropriate over-exposure of drug and potential dose related adverse events. 
  
Not only were the observed PK/PD ratios from the first TDM measurement highly 
variable, achieving the desirable level of drug exposure in subsequent TDM appeared to be 
difficult.  Paired comparison of first and subsequent TDM measurements in patients who had 
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more than one TDM did not show any significant improvement in the percentage of cases 
achieving the predefined PK/PD targets.  These observations were likely secondary to intra-
subject variability of pharmacokinetics throughout the antibiotic course278 and the less precise 
dose adjustment strategy we adopted in this study.  On the other hand, excessive beta-lactam 
dosing (as measured by upper dose reduction threshold of 100% fT>10xMIC) reduced with 
subsequent TDM.  Nevertheless, given only small percentage of our cohort had second TDM 
performed, the value of TDM in improving target attainment might not be reflected here.  
Better re-dosing strategies are needed in future studies to optimize the potential benefit beta-
lactam TDM could offer.126, 279, 280  
  
The secondary aim of this study was to describe factors associated with failure to 
achieve PK/PD targets.   Augmented renal clearance (calculated CLCR >130 mL/min) was 
found to be the strongest predicting factor for sub-therapeutic beta-lactams exposure in our 
cohort; despite the empiric dosing regimen had already been adjusted for substantial 
proportion of patients with suspected ARC.  The underlying mechanism of ARC in the 
critically ill is unclear; however there is emerging evidence that show high prevalence of the 
phenomenon and its association with sub-threshold beta-lactam concentrations in the severely 
ill.271, 281, 282  In an observational study by Huttner et al, in which the prevalence of ARC and 
sub-therapeutic beta-lactam concentrations in 100 critically ill patients treated with imipenem, 
meropenem, piperacillin/tazobactam or cefepime were evaluated, ARC was significantly 
associated with undetectable trough beta-lactam concentrations (OR=3.3).  Although we were 
unable to confirm association of ARC with negative clinical outcome in this study, and the 
correlation of ARC and outcome is still yet to be clarified,283 adjusted beta-lactam dosage and 
utilization of TDM is probably indicated in this group of patients who are theoretically at 
higher risk of clinical failure secondary to sub-optimal antibiotic exposure. 
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The association of clinical factors, in particular achievement of predefined PK/PD 
targets, with clinical failure were also explored in this analysis.  In the DALI Study, a large 
multinational beta-lactam point-prevalence PK study, increasing 50% fT>MIC and 100% fT>MIC 
ratios were associated with increased odds of positive clinical outcomes, but the effect was 
shown to be more significant in those with lower disease severity as measured by APACHE II 
score (of 0-14).81  Our patient population however falls into the more critically ill category 
with median APACHE II score of 22 [IQR = 16-27].  Whether this explains the lack of 
association found between respective predefined PK/PD targets and clinical outcome in this 
analysis, and the appropriate PK/PD target for this group of more critically ill patients would 
need to be clarified. 
 
Another noteworthy finding was the significantly increased odds in negative clinical 
outcome associated with abdominal infection.  In a recent large multi-center study, abdominal 
infection was found to be associated with significantly higher mortality as compared with 
other types of infection.284  Deranged pharmacokinetics of beta-lactams have been noted in 
patients with intra-abdominal infections,45 however information on optimizing beta-lactam 
PK/PD in this subgroup of patients was very limited.  Only 4 out of 41 deaths (9.8%) in this 
study were of intra-abdominal cause, yet our observation of increased treatment failure risk 
warrants further research to better individualize antibiotic dosing in this group of patients. 
 
Limitations of the study 
First, this is a single-centre study in which the wider generalizability of the results 
might be limited.  However, we have reported data from a relatively large cohort of patients 
enrolled with very broad inclusion criteria, and to the best of our knowledge this is the largest 
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dataset of directly measured unbound concentrations data of the studied drugs.  Second, use of 
data from selected indications (respiratory, abdominal and blood stream infections) only for 
outcome analysis might lead to biasing of the data for defining associations between PK/PD 
target attainment with clinical outcome.  However, no significant association was found either 
for patients treated for other indications or for the overall studied population (results not 
presented).  Thirdly, CLCR was estimated using the Cockcroft-Gault formula, which has 
tendency to under-estimated creatinine clearance in the critically ill population especially for 
those with augmented renal clearance.285, 286  However, estimation of renal function using 
measured creatinine clearance has its own practical issue in terms of urine sample collection 
and accessibility of the test.  Our findings highlight the risk of under-dosing in patients with 
calculated ARC, which is practically relevant in clinical practice where only estimated CLCR 
is available.  In addition, the dose adjustment strategy used in this study appears to have been 
sub-optimal and may have contributed to poor PK/PD target attainment with subsequent TDM 
measurements, which could be improved with use of dosing software based on Bayesian 
forecasting.79  The PK/PD targets were selected based on preclinical data and limited number 
of clinical studies as discussed above.  To date, there is still no validated unifying PK/PD 
target for beta-lactams in the critically ill population; the PK/PD targets selected for this 
analysis however cover the most conservative to most aggressive antibiotic exposures likely 
necessary for adequate clinical response.  Our results reinforce the sub-optimal antibiotic 
exposure observed across these target ranges. Clinical significance of this finding need to be 
further delineated, as this study was not specifically designed, and therefore might not be 
adequately powered to detect difference in outcome of patients who did or did not attain 
PK/PD targets.  Furthermore, we did not take into account the synergistic effect of other co-
administered antibiotics in this study, which potentially introduce bias in our analysis.  Lastly, 
in majority of the cases, measured MICs of the targeted pathogens were not available, or 
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culture was negative.  Therefore, the PK/PD ratios and associated results presented represent 
the worst-case scenario where the presence of least susceptible pathogen was assumed.  Yet, 
this assumption is acceptable and closely resembles clinical practice, where most MIC data 
are not available.  The use of EUCAST clinical breakpoints, which were derived to predict 
likelihood of therapeutic success, is clinically relevant and appropriate in practice.  
Nevertheless, this highlight the importance of developing methods that allow timely 
determination and application of MIC data in clinical setting in the future.287, 288 
 
In conclusion, our study indicates that optimal exposure of unbound beta-lactams, in 
particular, for drugs with lower protein binding, is not achieved in a significant proportion of 
critically ill patients using conventional or empirically adjusted dosing regimens.  Dosing 
strategies need to be redefined, especially for patients with ARC and intra-abdominal 
infections, who are at risk of sub-therapeutic exposure of beta-lactams and negative clinical 
outcome respectively.  Further clinical studies are needed to define better re-dosing methods 
as well as the implications of achieving targeted beta-lactams exposure with TDM on clinical 
outcomes. 
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5.3  Conclusion 
This chapter has described a large single-centre prospective observational study to define the 
attainment of pre-determined PK/PD targets for unbound beta-lactams in the critically ill.  We 
demonstrated the attainment of these theoretical optimal targets was poor, especially for lower 
protein-bound beta-lactams, even with empirical dosage adjustment and/or subsequent TDM.  
We were unable to correlate positive clinical outcome with any of the predefined PK/PD 
targets; however we identified subsets of patients, namely those with ARC and intra-
abdominal infection, were at high risk of under-dosing and negative clinical outcome 
respectively.  Out data support the need to redefine optimal PK/PD targets for beta-lactam 
TDM in the critically ill, especially for those identified to be at risk of poorer outcome.
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Chapter 6  The relationship of beta-lactam antibiotics exposure and clinical outcome  
in critically ill patients  
 
6.1  Synopsis 
The aim of this chapter is to characterize the PK/PD indices associated with positive clinical 
outcome in critically ill patients with gram-negative blood stream infection (BSI) treat with 
beta-lactams.  This retrospective analysis of databases from prospective studies explores the 
role of higher than standard beta-lactams exposure at the site of infection in the critically ill. 
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6.2 Manuscript entitled, “Beta-lactam pharmacodynamics in gram negative 
bloodstream infections (BSI) in the critically ill” 
 
The manuscript entitled, “Beta-lactam pharmacodynamics in gram negative bloodstream 
infections (BSI) in the critically ill” has been submitted for publication. 
 
The co-authors contributed to the manuscript as follows: All study design and data collection 
was performed by the PhD candidate, Gloria Wong, under the supervision of Prof. Jason A. 
Roberts. Analysis of data was performed by, under the guidance of Prof. Jason A. Roberts, 
Prof Jeffrey Lipman. The PhD candidate, Gloria Wong, took the leading role in manuscript 
preparation and writing. 
 
The manuscript is presented as the format intended for publication, except figures and tables 
have been inserted into the text at slightly different positions. Also, the numbering of pages, 
figures and tables has been adjusted to fit the overall style of the Thesis. The references are 
found alongside to the other references of the Thesis, in the section ‘Reference’. 
  104 
Beta-lactam Pharmacodynamics in Gram-negative Bloodstream Infections in the 
Critically Ill  
 
Gloria Wonga,b*, Fabio Tacconec, Paola Villoisc, Marc H. Scheetzd,e, Nathaniel J. Rhodesd,e, 
Scott BriscoeRf, Brett McWhinneyf, Maria Nunez-Nunezg, Jacobus Ungererf,h, Jeffrey 
Lipmana,b, Jason A. Robertsa,b,i 
 
a UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, 
Australia 
b Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia 
c Department of Intensive Care, Erasme Hospital, Universite´ Libre de Bruxelles, Brussels, 
Belgium  
d Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA 
e Department of Pharmacy Practice and Pharmacometrics Center of Excellence, Midwestern 
University, Chicago College of Pharmacy, Downers Grove, IL, USA 
e.2  Department of Pharmacology, College of Graduate Studies, Midwestern University, 
Chicago College of Pharmacy, Downers Grove, IL, USA 
f Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia 
g Department of Pharmacy and Department of Infectious Diseases, University Hospital San 
Cecilio, Granada, Spain 
h Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia 
i Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The 
University of Queensland, Brisbane, Queensland, Australia 
Word counts: Abstract 231; Main Body 1463 
 
  105 
* Address for correspondence 
Dr Gloria Wong 
Level 8 UQ Centre for Clinical Research, The University of Queensland,  
Royal Brisbane and Women’s Hospital  
Butterfield St, Brisbane Queensland Australia 4029 
Ph +614 3089 1636   Fax +617 3636 3542 
gloria.wong@alumni.utoronto.ca   
  106 
6.2.1 Abstract 
Objectives: To determine the beta-lactam exposure associated with positive clinical outcomes 
for Gram-negative blood stream infection (BSI) in critically ill patients. 
Patients and methods: Pooled data of critically ill patients with mono-microbial gram-negative 
BSI treated with beta-lactams were collected from two databases.  Free minimum 
concentrations (fCmin) of aztreonam, cefepime, ceftazidime, ceftriaxone, piperacillin (co-
administered with tazobactam) and meropenem were interpreted in relation to the measured 
MIC of targeted bacteria (fCmin/MIC).  A positive clinical outcome was defined as completion 
of treatment course or de-escalation, without other change of antibiotic therapy, and with no 
additional antibiotics commenced within 48 h of cessation.  Drug exposure breakpoints 
associated with positive clinical outcome was determined by classification and regression tree 
(CART) analysis. 
Results: Data from 98 patients were included.  Meropenem (46.9%) and 
piperacillin/tazobactam (36.7%) were most the commonly prescribed antibiotics. The most 
common pathogens were Escherichia coli (28.6%), Pseudomonas aeruginosa (19.4%) and 
Klebsiella pneumoniae (13.3%). In all patients, 87.8% and 71.4% achieved fCmin/MIC>1 and 
fCmin/MIC >5 respectively.  Seventy-eight patients (79.6%) achieved positive clinical 
outcome.  Two drug exposure breakpoints were identified, fCmin/MIC>1.3 for all beta-lactams 
(predicted difference in positive outcome 84.5% versus 15.5%, p<0.05) and fCmin/MIC>4.95 
for meropenem, aztreonam or ceftriaxone (predicted difference in positive outcome 97.7% 
versus 2.3%, p<0.05). 
Conclusion: A beta-lactam fCmin/MIC>1.3 was a significant predictor of a positive clinical 
outcome in critically ill patients with Gram-negative BSI and could be considered an 
antibiotic dosing target.  
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6.2.2 Introduction 
Gram-negative bloodstream infections (BSI) are associated with a high burden in critically ill 
patients, with mortality rates commonly exceeding 15%.289, 290  Emergence of resistant 
bacteria associated with ineffective initial therapy is an additional challenge faced by 
clinicians.  Beta-lactam antibiotics, with broad-spectrum activity against Gram-negative 
bacteria, are commonly used in this setting.   
 
The efficacy of beta-lactams is closely correlated with the percentage of time where unbound 
(or free) drug concentration remains above the MIC for the targeted bacteria (%fT>MIC).  
Early in vitro and animal studies suggest that, depending on the sub-class of beta-lactam, a 
pharmacokinetic/pharmacodynamic (PK/PD) index of at least 30-60% fT>MIC is required for 
bactericidal effect; however trough (minimum) antibiotic concentrations up to 5-6 x MIC 
(fCmin/MIC >5) have been associated with improved clinical outcomes in previous reports of 
patients with sepsis and/or lower respiratory tract infections.108, 109, 291   It follows that 
uncertainty remains as to what the optimal PK/PD index is for beta-lactams in critically ill 
patients, particularly in the context of Gram-negative BSI.  
 
In this study, we aim to describe beta-lactam pharmacodynamics in critically ill patients with 
Gram-negative BSI in order to define drug exposures that may be associated with improved 
patient outcomes. 
 
6.2.3 Patients and methods 
Patient selection 
Cases included in this analysis were selected from a database that was constructed using two 
prospectively collected datasets of critically ill adult patients in which included various 
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demographic, clinical outcome and pharmacokinetic data were available. The datasets were 
from the therapeutic drug monitoring (TDM) databases from the tertiary referral intensive 
care units within Erasme Hospital (Belgium)292 and Royal Brisbane and Women’s Hospital 
(Australia)293.  Inclusion criteria for the present analysis included a documented BSI caused 
by a single Gram negative pathogen, admission to an intensive care unit and age > 18 years. 
Exclusion criteria were presence of renal replacement therapy (RRT) and polymicrobial BSI. 
All participants were enrolled between 2009 and 2014.  Approval to analyse these data was 
granted by the local institutional review boards for respective cohorts. 
 
Beta-lactam antibiotics included for the analysis were aztreonam, cefepime, ceftazidime, 
ceftriaxone, piperacillin (co-administered with tazobactam) and meropenem.  Individual 
antibiotic, dosing, and infusion time were determined by the treating clinician and according 
to local guidelines.     
 
Data collection 
The definitions used for the clinical endpoints are presented in Table 6.1.  Data collection was 
conducted by trained staff at each participating centre and entered into an electronic case 
report form.  The database contained information on patient’s age, sex, weight, serum and 
urine creatinine concentrations, measured creatinine clearance (CLCR), APACHE II score 
(Acute Physiology and Chronic Health Evaluation II), BSI causative pathogen, calculated or 
directly measured unbound beta-lactam antibiotic concentration at trough to fCmin/MIC, and 
clinical outcome.  The MICs for the targeted pathogen were determined by the local 
microbiology laboratory using Etest or VITEK® 2 (bioMérieux, Inc., Durham, NC) automated 
system.   
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Table 6.1. Definitions of clinical outcomes 
Clinical outcomes 
Positive clinical 
outcome 
Completion of treatment course without change or addition of antibiotic 
therapy, and with no additional antibiotics commenced with 48 h of 
cessation.  De-escalation to a narrower spectrum antibiotic was 
permitted. 
Negative clinical 
outcome 
Any clinical outcome other than positive clinical outcome 
 
Sampling collection 
A single blood sample was taken from the participant at the end of a dosing interval (trough) 
at steady-state (defined as >24 hours after initiation of therapy).  Unbound drug concentration 
was analyzed by a validated protocol using ultra-filtration and HPLC with ultraviolet 
detection as previously described.140  
 
Statistical analysis 
Demographic, clinical, and PK/PD-related data are presented by number (%), mean  SD, or 
median [IQR], as appropriate.  Associations between patient or microbiological factors and 
patient outcome were assessed using Chi-square and Fisher’s exact analyses where 
appropriate for nominal data and Student’s t tests or Wilcoxon rank sum tests for interval 
data. The most significant drug exposure breakpoint associated with positive clinical outcome 
was determined by classification and regression tree (CART) analysis in line with previous 
studies.294, 295  A p<0.05 was considered statistically significant. 
 
6.2.4 Results 
6.2.4.1 Demographics and clinical data 
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Ninety-eight patients were eligible for this study.  The demographic and clinical features of 
the patients are described in Table 6.2.  The most frequently prescribed antibiotics were 
meropenem  (n=46; 46.9%), piperacillin/tazobactam (n=36; 36.7%), and ceftazidime (n=10; 
10.2%). Pathogens isolated are listed in Table 6.3. The most prevalent isolates and the 
corresponding MIC to the treatment antibiotics were Escherichia coli (n=28 (28.6%); median 
MIC=0.75mg/L [0.2–125]), Pseudomonas aeruginosa (n=19  (19.4%); median MIC=8 mg/L 
[0.1–256]) and Klebsiella pneumoniae (n=13 (13.3%); median MIC=3 mg/L [0.02–48]). 
 
Table 6.2. Demographics and clinical characteristics of studied patients 
Characteristics N=98 
Age (years) 60.5 (19-87) 
Male sex 58.5% 
BMI (m2/kg) * 26.1 (23.1-30.5) 
APACHE II score 19 (6-40) 
Measured creatinine clearance (mL/min)** 77.5 (4-402) 
Data shown are expressed as n (%), or median (IQR) 
* Data only available for 79 patients 
** Based on 24-hour urinary creatinine clearance 
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Table 6.3. Microbiological pathogens of BSI (N=98) 
PATHOGENS  n (% of cases) 
Acinetobacter baumanii 1 (1.0) 
Citrobacter koseri 2 (2.0) 
Enterobacter aerogenes 4 (4.1) 
Enterobacter cloacae 9 (9.2) 
Escherichia coli 28 (28.6) 
Klebsiella oxytoca 5 (5.1) 
Klebsiella pneumoniae 13 (13.3) 
Klebsiella spp. 2 (2.0) 
Morganella morganii 3 (3.1) 
Pseudomonas aeruginosa 19 (19.4) 
Proteus mirabilis 9 (9.2) 
Proteus vulgaris 1 (1.0) 
Serratia liquefaciens 1 (1.0) 
Serratia marcenses 1 (1.0) 
 
6.2.4.2 Clinical Outcome and PK/PD Data  
The daily antibiotic doses, fCmin/MIC ratios and clinical outcome data are shown in Table 6.4.  
Overall, 71.4% of patients had a fCmin/MIC ratio of five or above.  Seventy-eight (79.6%) 
patients had a positive clinical outcome. There was a large variation in fCmin/MIC.  No 
significant difference in the median APACHE II scores for patients with positive and negative 
clinical outcomes was found (20 [IQR, 10–40] and 20.5 [IQR, 10–35] respectively).  Other 
patient or microbiological chacteristics including BMI and CLCr were not significantly 
associated with patient outcome. 
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Table 6.4. PK/PD index and clinical outcome for studied beta-lactam antibiotics in critically 
ill patients treated for Gram negative BSI.  PK/PD outcome was measured in terms of ratio of 
unbound trough (fCmin) to MIC of pathogen for corresponding beta-lactams.  Data are 
described as n (%) or median (IQR).  
Antibiotic 
n (%) 
Daily Dose 
(g) 
fCmin/MIC ratio Positive clinical outcome  
n (%) < 1 = 1-5 > 5 
Aztreonam, 2 
(2.0%) 
7.0 (6.0-5.0) - - 2 (100) 2  (100%) 
Ceftazidime, 
10 (10.2%) 
6.0 (4.0-
12.0) 
- 3 (30) 7 (70) 7 (70%) 
Cefepime, 2 
(2.0%) 
6.0 (6.0-6.0) 2 (100) - - 0 (0%) 
Ceftriaxone, 2 
(2.0%) 
- - - 2 (100) 2 (100%) 
Meropenem, 
46 (46.9%) 
3.0 (2.0-6.0) 3 (6.5) 4 (8.7) 39 (84.8) 42 (91.3%) 
Piperacillin/taz
obactam, 36 
(36.7%) 
16.0 (8.0-
16.0) 
7 (19.4) 9 (25) 20 (55.6) 25 (69.4%) 
Overall (N=98)  12 (12.2%) 16 (16.3%) 70 (71.4%) 78 (79.6%) 
 
A positive clinical outcome was associated with fCmin/MIC >1.3 (Figure 6.1), with 84.5% of 
patients achieving this exposure manifesting a positive clinical outcome. For patients 
receiving meropenem, aztreonam or ceftriaxone, a higher ratio of fCmin/MIC >4.95 were 
found to be associated with positive clinical outcome, with 97.7% of these patients 
manifesting a positive clinical outcome (Figure 6.2).  
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Figure 6.1. CART analysis for association of fCmin/MIC with positive clinical outcome in all 
studied patients (N=98; p<0.05).  Positive outcome was associated with Cmin/MIC ratio of 
>1.3. 
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Figure 6.2. CART analysis for association of fCmin/MIC ratio with positive clinical outcome 
in patients, according to beta-lactam antibiotics received.  Positive clinical outcome is 
associated with significantly higher fCmin/MIC ratio of >4.95 in patients received meropenem, 
aztreonam or ceftriaxone (N=50; p<0.05). 
 
Legend: CAZ - ceftazidime, CEF - cefepime, TZP – piperacillin/tazobactam, MEM - meropenem, AZT - 
azteonam, CRO - ceftriaxone 
 
6.2.5 Discussion 
In this study, we have observed that positive clinical outcome in critically ill patients with 
Gram-negative BSI was associated with an unbound trough beta-lactam concentrations 1.3-
times the MIC of the causative pathogen.  We also found that a higher exposure of fCmin/MIC 
>4.95 was significantly associated with an even higher positive clinical outcome (97.7% 
positive clinical outcome) in patients specifically treated with meropenem, aztreonam or 
ceftriaxone.  
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The pharmacodynamic results of this study support the findings from previous smaller cohort 
studies in patients with other infection syndromes and which included either actual measured 
drug exposures, or simulated drug exposures.  In an open-label study involving 36 patients 
with Gram-negative infection treated with cefepime, Tam et al demonstrated that 80% 
microbiological success was correlated with a minimum of 83% fT>4.3xMIC.
108  No association 
with clinical success was demonstrated in that study, and this was attributed to the relatively 
small sample size.  In another study of 33 patients with Gram-negative pneumonia treated 
with cefepime, a fCmin/MIC ratio of  >2.1 was found to be associated with significantly lower 
risk of clinical failure (failure defined as persisting symptoms, change in antibiotic therapy 
and/or mortality).291  One may expect a higher antibiotic concentration is necessary for 
treating pneumonia to achieve adequate local exposure at site of infection,296 however the 
discrepancy found could be due to a much lower severity of illness (median APACHE II score 
of 13) as compared to our patient cohort where the median APACHE II score was 20.  A third 
study used dosing simulations from a population pharmacokinetic model developed in 
patients with lower respiratory tract infections treated with meropenem, conclude that a 
fCmin/MIC ratio of >5 was associated with positive clinical (failure defined as persisting 
symptoms, change in antibiotic therapy and/or mortality) and microbiological outcomes.109   
 
It should be noted that each of these previous studies included only one drug in their analyses 
and the transferability of such results to other beta-lactams has been unclear.  The results of 
the present study supports those previously described exposures confirming that these 
exposures exceeding the MIC are also beneficial in BSI and are likely a class effect for beta-
lactams, including piperacillin/tazobactam, in critically ill patients.  Our results also advance 
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the previous studies by measuring concentrations at the site of infection, which in the case of 
blood, which should be sterile, the causation of the pathogen and infection is more likely.   
 
Our study has several limitations.  Firstly, the number of cases in the analysis is relatively 
small to measure the effects of drug exposure on patient outcome. However, it is the largest 
sample to date where actual measured concentrations have been analysed in this manner.  
Significance was only demonstrated when data for several studied antibiotics were 
aggregated, which might introduce bias associated with stratifying based on selected 
antibiotics.  Also, we were unable to examine and control the impact of other important 
variables that were previously shown to be an independent factor associated with mortality, 
such as presence of resistant organisms and clinical severity.297, 298  Nevertheless, we 
demonstrated a PK/PD threshold that is most likely to be associated with clinical success for a 
group of broad-spectrum beta-lactams, providing an important insight into pharmacodynamic 
endpoint for future TDM studies of this frequently used antibiotic group in the critically ill.   
 
In conclusion, this analysis demonstrated that fCmin/MIC >1.3 was significantly associated 
with a positive clinical outcome in critically ill patients with Gram-negative BSI. In patients 
treated with meropenem, ceftriaxone and aztreonam, the attainment of a higher unbound 
antibiotic exposure as measured by fCmin/MIC>4.95 was predictive of positive clinical 
outcome in an ever higher proportion of patients.  These results warrant validation by 
interventional prospective studies with larger sample size to test whether optimized beta-
lactams dosing in critically ill patients with Gram-negative BSIs can improve patient 
outcomes when a fCmin/MIC >1.3 is achieved. 
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6.3  Conclusion 
This chapter further explored the PK/PD index associated with positive clinical outcome in 
critically ill patients with BSI.  By studying patients with BSI, we chose to analyse 
concentrations of beta-lactams at the site of infection which is likely to make the analysis 
more relevant.  Using CART analysis, we found that overall exposure of fCmin/MIC >1.3 is 
necessary for positive clinical outcome.  Antibiotic exposure as measured by fCmin/MIC>4.95 
was needed for patients treated with meropenem, ceftriaxone and aztreonam, which is much 
higher than the PK/PD index conventionally thought to be optimal.  These data suggested a 
higher PD endpoint might be necessary for future studies to validate the role of beta-lactams 
TDM in the critically ill.
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Chapter 7  General conclusion 
The bug, drug, and host interaction is dynamic, yet of paramount importance in determining 
the success of antimicrobial therapy.  In the critically ill, understanding and optimizing 
PK/PD within this relationship is of significant importance given the unpredictability and 
variability in PK of antibiotics in this population, and frequency of difficult to treat infections 
encountered.  TDM of beta-lactams in the critically ill patients provides theoretical 
advantages and some early clinical evidence to overcome these challenges, yet the optimal 
practical modality and associated PK/PD indices are still to be defined. 
 
7.1 Summary of findings 
In this Thesis, a structured review of published literature was performed to summarize the 
current evidence of TDM practice in various groups of antibiotics, including beta-lactams, in 
the critically ill.  Our analysis revealed significant data demonstrating the insufficiency of 
standard dosing regimens in attaining adequate antibiotic concentrations in this population.  
The use of TDM to maximize the therapeutic effects of antibiotics, especially for beta-
lactams, appears to be feasible, but need to be further defined and validated. 
 
Given the above findings, we sought to identify the key processes and PK/PD targets adopted 
by institutions known to perform beta-lactam TDM routinely in their practice.  An 
international multi-centre survey (n=9) revealed significant variability in practice in terms of 
patient and antibiotic selection for the process, and drug assay.  The observed variable PK/PD 
targets and dose adjustment strategies used among the institutions highlights the importance 
of further defining these parameters to improve beta-lactam TDM application in the critically 
ill patients. 
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It is well understood that the efficacy of beta-lactams is related to the unbound fraction of the 
drug in a time-dependent manner; however the impact of hypoalbuminaemia on unbound 
beta-lactams PK has not been well defined, despite the prevalence of the phenomenon in the 
critically ill population.  Part of this Thesis has specifically addressed this issue.  We 
compared the directly measured unbound beta-lactam concentrations, with the unbound beta-
lactam concentrations calculated from measured total concentrations using published protein 
binding data.  We demonstrated poor predictive performance of the conventional method 
when applied to the critically ill population, and significant differences between measured and 
predicted unbound drug concentrations were found for the highly protein bound beta-lactams.  
The correlation of the percentage of unbound beta-lactam concentrations with albumin 
concentrations was limited.  These results support the direct measurement of unbound beta-
lactams for TDM, which the equipment and validated protocol are equally assessable as the 
conventional method. 
 
In view of the potential clinical advantages of measuring unbound beta-lactam concentrations 
directly for TDM, we further applied this method and assess the PK of unbound beta-lactams 
in a large cohort of critically ill patients (330 patients, 369 clinical episodes).  Attainment of 
predefined PK/PD targets was again demonstrated to be low, especially for lower protein-
bound beta-lactams.  Patients with ARC were at higher risk of not achieving PK/PD targets of 
100% fT>MIC and 100% fT>4xMIC, despite empiric dose adjustment.  The heterogeneity of the 
studied cohort and lack of power of the study make the correlation of PK/PD targets and 
clinical outcome challenging.  More sophisticated dose adjustment strategies are needed given 
the observed difficulty in achieving desired beta-lactam concentrations in subsequent TDM.  
Nevertheless, we identified sub-groups of critically ill patients at higher risk of sub-optimal 
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dosing and/or negative clinical outcome, in which benefit of beta-lactam TDM would need to 
be further clarified.   
 
The last part of this Thesis is a focused analysis of the association of PK/PD index with 
positive clinical outcome in critically ill patients with Gram-negative BSI.  Given the 
theoretical and clinical advantages of higher than conventional beta-lactam exposures 
documented in small number of literature, we seek to demonstrate this by measuring beta-
lactam concentrations at the site of infection, which is the blood.  Our results suggest that a 
fCmin/MIC>1.3 is needed for all studied beta-lactams, and a higher target of fCmin/MIC>4.95 is 
needed for meropenem, aztreonam or ceftriaxone.  These targets are significantly higher than 
the conventional targets of 30-60% fT>MIC which depend on the beta-lactam used.  Our 
analysis was limited by small number of data available for some beta-lactams, however these 
findings warrant to be validated in a larger randomized controlled study of beta-lactam TDM. 
 
7.2 Suggested future directions 
In this Thesis, we demonstrated significant variations in unbound beta-lactam PK in the 
critically ill, which may contribute to therapeutic failure.  The impact of hypoalbuminaemia 
on beta-lactam TDM is of significance in this population.  We have defined subset of 
critically ill patients at risk of sub-optimal beta-lactam dosing and negative clinical outcome.  
Moving forward, the following strategies and studies are suggested: 
 
1. There is considerable advantage in directly measuring beta-lactam concentrations 
for TDM in clinical study and in practice.  Adaptation of this method is suggested 
if available, especially in practice and future larger clinical studies to confirm the 
clinical benefit of beta-lactam TDM in targeted critically ill patient groups.  The 
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impact of hypoalbuminaemia needs to be taken into consideration when analysing 
data based on calculated unbound beta-lactam concentrations.299 
2. The theoretical benefit of beta-lactam TDM still persists in view of the deranged 
PK observed in the critically ill.  An increasing amount of clinical evidence 
supports the use of higher than conventional PK/PD targets to be used in beta-
lactam TDM, and demonstrated in this Thesis as well.  Larger prospective 
randomized clinical trials, using targeted drug exposure of at least fCmin/MIC>1.3, 
or higher targets of fCmin/MIC>4.95 for subsets of patients at risk of negative 
outcome (eg. abdominal infection), are suggested to quantify the clinical benefit of 
beta-lactam TDM. 
3. Strategies for dose adjustment are observed to be variable and lack of precision.  
Given an accurate and timely dose adjustment strategy is complementary to TDM, 
more efforts are needed to develop and validate dosing nomograms and PK 
softwares to be used in beta-lactam TDM in the critically ill population. 
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